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1 INTRODUCTION 
1.1 Cancer and current treatment options 
Cancer is the second leading cause of death of humans worldwide and the incidence of 
suffering from cancer has increased by approximately two million cases from 2008 to 
2012.1 Despite the development of detecting cancer early, the improved pharmacological 
and surgery treatment as well as healthier life styles, fighting cancer is still one of the 
greatest burdens in modern medicine. Not only risk factors such as tobacco, obesity and 
chronic infections, but also epidemiological influences and the genetic background have 
an impact on cancer incidence and are challenges for cancer treatment.1 Radiation and 
pharmacological medication are, after surgery, the state of the art treatment of tumors.2 
Among others, the treatment strategies of breast cancer have made progress over the 
last years. Prominent chemotherapeutic strategies in breast cancer treatment are 
hormone targeted therapy, for example with the estrogen receptor modulator 
tamoxifen.3 Also antibodies against growth factor receptors, like trastuzumab are in 
clinical use.4 Furthermore, research focuses more on prophylactic vaccination of infection 
dependent tumor development, as it is the case for hepatitis B and human papilloma 
viruses.5 Nevertheless, classic chemotherapy, such as the anthracycline-antibiotic, 
doxorubicin and taxanes like paclitaxel are still in use and are an important part in clinical 
treatment.6 The malignant transformation of a mammalian cell could be induced by 
cancerogenous factors, such as chemicals, radiation and viruses. Cancer is a multifactorial 
disease and more than one genetic alteration of a human cell is necessary to develop 
malignancy.7 Thus, the commonly used pharmacological high dose monotherapy, wherein 
the tumor survival capacity is targeted unspecifically, seems to be outdated and novel 
therapeutic options are needed. For instance, doxorubicin was proven to be more 
effective in combination therapy with the DNA alkylating agent ifosfamide in comparison 
to single treatment.8 Hence, combination treatments of two or more chemotherapeutics 
are promising approaches for advanced cancer therapy, since they reduce the probability 
 
 
INTRODUCTION 
 
2
 
of resistance mechanisms in cancer. In addition, many pharmacological therapies induce 
strong side effects, e. g., nausea, hair loss, or even neurotoxicity and cardiotoxicity, which 
impair quality of life and affect life expectancy.9 Besides doxorubicin, cytoskeletal 
affecting drugs such as microtubule targeting paclitaxel are often used in pharmacological 
treatment of cancer, but are still accompanied by strong side effects, like peripheral 
neuropathy.10 
A further hallmark of many types of cancer is the metastatic dissemination of cells. 
Herein, cells of the primary tumor undergo transformation and obtain a motile and 
invasive phenotype.11 One example for a chemotherapeutic drug, which targets the 
metastatic dissemination of cancer cells, is the Src tyrosine kinase family inhibitor 
saracatinib. It successfully inhibits the extravasation of metastatic tumor cells resulting in 
inhibition of breast cancer brain-metastasis in the clinic.12 Despite promising 
investigations for the inhibition of metastasis in cancers, such as the integrin inhibitor 
cilengitide, new options and approaches for cancer therapy are urgently needed.13,14 
1.2 Actin cytoskeleton as potential target 
 Actin structure and physiological function 1.2.1
One promising target for new therapeutic approaches in cancer treatment is the 
cytoskeleton of tumor cells. The cytoskeleton consists of three different structural 
components, which interact with each other and build a dynamically regulated three 
dimensional network. The cytoskeleton network is characterized by associating and 
dissociating monomer units, which polymerize or depolymerize to filament structures.15 
In comparison to the intermediary filaments (10 nm) and microtubules (25 nm), the actin 
filaments are the smallest components of the cytoskeleton, with a diameter of 7 nm. 
Actin is a 42 kDa globular expressed protein with three different isoforms. Fifty percent of 
all proteins contained in the muscles is α-actin, whereas β- and γ-actin occur in 
non-muscle tissue and function as mechanical stabilizer for cell shape, cell migration, and 
intracellular transport processes.16 The actin structures build a contractile ring during 
cytokinesis of mammalian cells and are therefore crucial for cell division and proliferation. 
During cell migration actin participates in the formation of cellular protrusions and is 
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responsible for cellular contractility.17 Besides the cytoplasmic form, actin is also present 
in the nucleus of mammalian cells and plays an important role in modulatory processes, 
like the regulation of transcription by interacting with RNA-polymerases,18,19 and nuclear 
translocation of the transcription co-activator MRTF-A,20 as well as chromatin 
remodeling.21 There are also some hints that nuclear actin might participate in the DNA 
damage repair machinery.22,23  
The polymerization of actin filaments is a very dynamic process. A minimum of four 
G-actin subunits assemble spontaneously or through actin binding proteins to the 
nucleation complex, which further builds actin filaments (F-actin) by adding of ATP bound 
G-actin subunits.24 The polymerization is faster at the barbed end, whereas 
depolymerization proceeds predominantly at the pointed end.25 More complex structures 
of actin are formed by additional actin regulating proteins.25,26 For example, gelsolin or 
cofilin/actin depolymerizing factor bind to F-actin, followed by severing and actuating the 
actin depolymerization. Furthermore, capping proteins block the barbed end and inhibit 
the elongation of F-actin. Branched actin filaments are important at the leading edge of 
motile and migrating cells. In addition, the actin polymerizing complex Arp2/3 is an 
important regulator of actin dynamics and facilitates the assembly of new filaments in an 
angle of 70° to existing filaments (Figure 1.1).15,25 Since decades it is known that natural 
compounds like phalloidin or cytochalasin D have an impact on actin dynamics.27 
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 The actin binding compounds chondramide B and miuraenamide A 1.2.2
Compounds from different natural sources such as plants, marine organisms, and 
microorganisms have been applied for centuries in the treatment of cancer and infectious 
diseases.28 The natural compounds and their derivatives represent the major part of anti-
cancer drugs used in clinics and a high number of natural compound-derived substances 
currently undergo clinical trials.29 One important source of potent substances are 
myxobacteria.30 For instance, the epothilone from Sorangium cellulosum is in clinical use 
for breast cancer treatment and underlines the potency of natural compounds derived 
from myxobacteria, targeting the cytoskeleton.31 Two further examples of myxobacteria-
derived natural compounds are chondramide and miuraenamide.  
Chondramides are cyclodepsipeptides (Figure 1.2 A), which are produced by the 
myxobacteria strain Chondromyces crocatus. First studies with chondramide indicated 
cytostatic effects on carcinoma cell lines by affecting the actin cytoskeleton dynamics.32 
We recently demonstrated the very specific in vitro effects on breast cancer cell lines in 
comparison to non-cancer cells.33 Further studies on the metastatic inhibitory capacity of 
chondramide achieved promising results in animal experiments.34  
 
Figure 1.1: The actin structure and its dynamics. A: Four G-actin monomers assemble with ATP to 
the nucleation complex, which starts the actin polymerization. The elongation of F-actin is faster 
at the barbed end (B) in comparison to the pointed end (P). ATP is hydrolyzed to ADP followed by 
depolymerization predominantly at the pointed end. The exchange of ADP to ATP of G-actin 
restarts actin polymerization. B: Actin binding proteins regulate the severing, capping and 
branching of F-actin. 
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Miuraenamides are structurally related to the similarly functioning chondramides. 
Miuraenamide A (Figure 1.2 B) was isolated in the marine environment in Japan from the 
halophilic myxobacteria strain Paraliomyxa miuraensis. In line with chondramide it has a 
cyclodepsipeptide structure with a halogen atom. Biological examinations showed an 
antibiotic activity and inhibitory effects on NADH oxidase in higher doses.35 Additionally, 
miuraenamide is able to stabilize the actin cytoskeleton, similar to chondramide, and 
leads to a disruption of the actin cytoskeleton in different cell lines.36 The cytotoxic 
activity of miuraenamide on mammalian cells was briefly examined and achieved 
promising results in vitro.37 Both compounds are actin stabilizing agents, which lead to a 
hyperpolymerization of actin followed by an actin agglomeration in the cytoplasm of 
mammalian cells.32,36 
1.3 DNA damage response (DDR) 
Mammalian cells could encounter DNA damages through different stimuli and have to 
react with repair mechanisms. The cells which fail to repair their DNA damages, initiate 
apoptosis in the final instance. As an example, the DNA damage occurs during the 
replication, where the DNA double strands have to be unwound, broken, and rejoined by 
the topoisomerase II for sufficient DNA replication.39 Disruption of this replication process 
ends up in DNA double strand breaks (DSB).40 Exogenous factors like the exposure to 
radiation or chemicals induce mutagenic alteration of the DNA. Thus, mammalian cells 
have a tightly regulated repair machinery to initiate the response mechanisms and to 
avoid extensive damages of the DNA. The initial step of DNA damage response (DDR) is 
the recognition of DNA lesions by activated repair proteins, which attach on the damage 
 
Figure 1.2: The chemical structure of two actin binding compounds. A: Chondramide B38 and 
B: Miuraenamide A35. 
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site of the DNA strand. For instance, important DNA repair downstream kinases are the 
ataxia telangiectasia mutated (ATM) or ATR (ATM- and Rad3-related) proteins in 
homologous recombination and the Ku/DNA-dependent protein kinase (DNA-PK) catalytic 
subunit complex in non-homologous end-joining.41 Furthermore, the activation of DNA-PK 
by autophosphorylation not only results in repair complex formation, but also in the 
activation of telomere regulation42 and changes of the Golgi structure.43 Those repair 
enzymes could phosphorylate the histone 2A.x (γH2A.x) amongst others, which is a 
predictor for DSB and the recruiter of the repair machinery.44 The tightly regulated DDR 
was discussed to be influenced by alterations of the actin dynamics.23 
 DDR via the Golgi complex 1.3.1
The Golgi complex primarily coordinates the sorting and secretion of proteins and is 
associated to the actin cytoskeleton. In 2009, the group of Field published the alteration 
of Golgi constellation around the nucleus, influenced by a DNA damage signaling cascade 
depending on actin network as a transmission system.43,45 The Golgi membrane is 
anchored to the actin cytoskeleton via a complex of transmitting proteins. Following the 
induction of DNA damage by radiation or chemicals, the repair kinase DNA-PK is 
activated. Further on, the DNA-PK phosphorylates the Golgi phosphoprotein 3 (GOLPH3) 
at Thr143/Thr148 residues, which is linked to the Golgi membrane via the 
phosphatidylinositol-4-phosphate (PI4P).45 Under physiological conditions, the 
phosphorylation drives the binding of GOLPH3 to the unconventional myosin 18A 
(Myo18A) and increases the Golgi area via a tensile force of the associated actin 
cytoskeleton (Figure 1.3). The Golgi dispersal was described to be independent of 
apoptosis, but the efficient signaling cascade of the Golgi complex is essential to the 
survival after DNA damage induction.43 Thus, the inhibition of Golgi dependent DDR 
represents a novel promising approach for the combined treatment of DNA damaging and 
actin binding compounds. 
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 The DNA damaging agent doxorubicin 1.3.2
Doxorubicin (Doxo), or adriamycin, is a widely applied chemotherapeutic agent in 
neoplastic diseases. For instance, it has been clinically used for decades for treatment of 
various cancer types, including lymphomas, carcinomas, breast and ovarian cancers.9 It 
was first isolated from Streptomyces peucetius47 and along with its precursor 
daunorubicin, Doxo is related to the anthracycline class of antitumor antibiotics. The 
chemical structure is depicted in Figure 1.4, which shows the characteristic tetracycline 
part with substituted glycosyl residue. Doxo induces DNA damages by intercalating into 
the DNA double strand. It inhibits the DNA topoisomerase II by building a complex with 
the DNA and topoisomerase II, which leads to persistent DNA damage. Under 
physiological conditions, the topoisomerase II induces DNA double strand breaks to 
support sufficient DNA replication, transcription, and recombination. Highly proliferating 
cells, such as tumor cells, express elevated amounts of the enzyme.48 Another mode of 
action of Doxo is the formation of reactive oxygen species (ROS), which are mainly 
produced in the mitochondria. However, the exact mechanism by which Doxo induces 
 
Figure 1.3: The Golgi dispersal signaling cascade after DNA damage induction. The DNA 
dependent protein kinase (DNA-PK) is activated due to DNA damage and phosphorylates the Golgi 
phosphoprotein 3 (GOLPH3), which is linked via phosphatidylinositol-4-phosphate (PI4P) to the 
Golgi membrane (in green). The phosphorylation (Pi) of GOLPH3 induces enhanced binding of the 
unconventional myosin 18A (Myo18A), which is further linked to the actin cytoskeleton. The 
signaling cascade, which is activated by DNA damage, induces a tensile force to the Golgi complex 
and leads to the Golgi dispersal.46 
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ROS is still under debate. It is supposed that Doxo is converted by the NADPH 
dehydrogenase of the mitochondrial electron transport chain, to a semiquinone radical. 
Those effects on mitochondria were discussed to cause the cardiotoxicity. Therefore, the 
limiting factor of Doxo treatment in clinics is the long-term cardiotoxic effect in patients.49 
However, Doxo is still one of the main chemotherapeutic drugs used in the clinic. This 
reinforces the need to find novel combination partners for Doxo in order to lower side 
effects in patients. 
1.4 Cell migration 
Besides the regulation of DDR mechanisms, actin also participates in the migration of 
mammalian cells. The migration of cells is crucial for physiological processes such as 
embryogenesis, immune response, and the building of blood vessels.50 However, 
migration also participates in the development of pathophysiological processes, above all 
tumorigenesis and the formation of metastasis.11 The cell locomotion consists of different 
steps, and two dimensional (2D) migration differs from the migration in a three 
dimensional (3D) environment.51 During the movement over a 2D substrate, the 
migrating cell builds protrusions at the migration site, detaches and adheres to the 
substrate and moves by force generation by means of the actin cytoskeleton.50,52 In 
contrast, the cells in 3D migration have to coordinate and pave their way by sensing 
nutrition gradients, by proteolysis of extracellular matrix (ECM), or deformation through 
restricted pores on their path. First, 3D moving cells polarize, build protrusions, and 
adhere to parts of the ECM (Figure 1.5 a and b). These cancer cells are able to adapt to 
ECM alterations by their changes of migration mode from the “mesenchymal” type, under 
available space, to the “amoeboid” type, under limited space conditions (Figure 1.5 c). In 
addition, the cytoplasm and nucleus have to be deformed and pushed through the 
 
Figure 1.4: Chemical structure of doxorubicin.47 
 
 
INTRODUCTION 
 
9
 
restricted area. Finally, the cell moves forward by actomyosin contraction and 
de-adhesion and retraction from their back site (Figure 1.5 d and e).53 Consequently, the 
cell migration in 3D environment represents a complex machinery, which is, however, 
more representative for in vivo conditions.  
  
 
Figure 1.5: Steps of restricted 3D cell migration. Polarization/protrusion (a) and adhesion (b) to 
extracellular matrix (ECM), deformation of the cytoplasm and the nucleus dependent on physical 
space through a restricted pore (c, blue arrows with red circle), actomyosin contraction (d) and 
retraction (e) lead to forward movement of the cell (black arrow).53 
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1.5 Aim of the study 
In contrast to microtubule binding drugs, actin binding compounds have not been 
established in clinical use of cancer treatment, so far. The occurrence of resistance 
mechanisms and assumed side effects in patients are still limiting the use of actin binding 
compounds in clinic. However, actin participates in many regulatory cellular processes 
and therefore represents an attractive target for anti-tumor therapy.  
The aim of the study was, to elucidate differentiated effects of actin binding compounds 
chondramide and miuraenamide on cancer cells beside the prominent actin disruption. 
For this purpose, the myxobacteria derived compounds should be tested on two major 
hallmarks of cancer cells: the survival and the migration. Firstly, the impact on cancer cell 
survival after chondramide treatment in combination with DNA damaging agent 
doxorubicin, as well as the underlying mechanism should be evaluated. Secondly, we 
wanted to explore the effects of low dose miuraenamide treatment over a longer period 
of time on cancer cell migration processes.  
In summary, this study aimed to evaluate the pro-apoptotic and anti-metastatic potential 
of actin binding compounds, beyond simple cytoplasmic actin alterations. 
 
Figure 1.6: Actin binding compounds as a tool for cancer therapy. A: The first aim of the study 
was to elucidate the effect of chondramide B in combination with the DNA damaging agent 
doxorubicin concerning DNA damage response mechanism and cancer cell survival pathways. 
B: The second aim of the study was to analyze low dose effects of miuraenamide on the migration 
of cancer cells. 
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2 MATERIALS AND METHODS 
2.1 Materials  
 Study compounds 2.1.1
Chondramide B was kindly provided by Prof. Dr. Rolf Mueller, Helmholtz Centre for 
Infection Research, Saarland University, Saarbruecken, Germany. Miuraenamide A was 
kindly provided by Prof. Dr. Uli Kazmaier, Institute for Organic Chemistry, Saarland 
University, Saarbruecken, Germany. Both natural compounds were dissolved in DMSO 
and stored at -20°C. Doxorubicin, dissolved in H2O and DNA-PK inhibitor NU7026, 
dissolved in DMSO, were purchased from Sigma Aldrich, Taufkirchen, Germany. 
 Chemicals and reagents 2.1.2
The chemicals and reagents were purchased from Sigma Aldrich, Taufkirchen, Germany, 
unless otherwise listed in the following tables. 
Table 2.1: Chemicals and reagents 
Reagent Provider 
2,2,2-trichloroethanol Sigma Aldrich, Taufkirchen, Germany 
2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic 
acid) 
Sigma-Aldrich, Taufkirchen, Germany 
Agarose, low gelling temperature Sigma Aldrich, Taufkirchen, Germany 
Amersham Hybond ECL 
nitrocellulose membrane 
GE Healthcare Europe, Freiburg, Germany 
Amersham Hybond P 0.45 PVDF 
membrane 
GE Healthcare Europe, Freiburg, Germany 
Amphotericin B PAA Laboratories, Pasching, Austria 
Blotto (non-fat dry milk powder) Carl Roth, Karlsruhe, Germany 
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Reagent Provider 
Bovine Serum Albumin (BSA) Sigma Aldrich, Taufkirchen, Germany 
Bradford reagent Roti®-Quant Carl Roth, Karlsruhe, Germany 
Brefeldin A Sigma Aldrich, Taufkirchen, Germany 
CellTiter-Blue® Promega, Mannheim, Germany 
Collagen type I, rat tail ibidi, Martinsried, Germany 
CompleteTM Roche diagnostics, Penzberg, Germany 
Dimethylsulfoxide (DMSO) Sigma Aldrich, Taufkirchen, Germany 
FluorSaveTM Reagent Millipore, Darmstadt, Germany 
FuGENE® HD Transfection Reagent Promega, Mannheim, Germany 
GelRedTM Nucleic Acid Stain Biotium, Fermont, USA 
Hoechst 33342 Sigma Aldrich, Taufkirchen, Germany 
Luminol AppliChem, Darmstadt, Germany 
Na3VO4 Sigma Aldrich, Taufkirchen, Germany 
Page Ruler Prestained Protein 
Ladder 
Fermentas, St. Leon-Rot, Germany 
Propidium iodide Sigma Aldrich, Taufkirchen, Germany 
Pyronin Y AppliChem, Darmstadt, Germany 
Pyruvate PAA Laboratories, Pasching, Austria 
Rhodamine-phalloidin Life Technologies, Darmstadt, Germany 
Rotiphorese® Gel 30 (37,5:1) Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Tris hydrochloride (Tris HCl) Sigma Aldrich, Taufkirchen, Germany 
Triton® X-100 Millipore, Darmstadt, Germany 
Tween® 20 VWR, Darmstadt, Germany 
Yo-Pro®-1 Iodide ThermoFischer Scientific, Germering, Germany 
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 Cell culture reagents 2.1.3
Table 2.2: Cell culture reagents 
Cell culture reagent Producer/Distributor 
Boyden chamber Corning, New York, USA 
Collagen G Biochrom, Berlin, Germany 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
PAN Biotech, Aidenbach, Germany 
Endothelial cell growth medium 
ECGM 
Promocell, Heidelberg, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Carl Roth, Karlsruhe, Germany 
Fetal Calf Serum (FCS) PAA Laboratories, Pasching, Austria 
Glutamine Sigma Aldrich, Taufkirchen, Germany 
McCoy’s medium PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
RPMI 1640 10x medium Sigma Aldrich, Taufkirchen, Germany 
RPMI 1640 medium PAN Biotech, Aidenbach, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
 Mixtures and kits 2.1.4
Table 2.3: Mixtures and kits 
Name Provider 
Dual-Luciferase® Reporter Assay 
System 
Promega, Mannheim, Germany 
High-Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems, Foster City, USA 
Qiagen RNeasy® Mini Kit Qiagen, Hilden, Germany 
SYBR® Green PCR Master Mix ThermoFischer Scientific, Germering, Germany 
VECTASTAIN® ABC Kit  Vector Laboratories, Burlingame, USA 
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 Antibodies 2.1.5
Table 2.4: Primary antibodies 
Antibody (primary) Provider 
Actin (C4) Millipore, Darmstadt, Germany 
GAPDH (7B) Santa Cruz Biotechnology, Heidelberg, Germany 
GM130 (D6B1) New England Biolabs, Frankfurt (Main), Germany 
Ki67 Abcam, San Francisco, USA 
Myo18A Proteintech Group, Rosemont, USA 
NFAT5 ThermoFischer Scientific, Germering, Germany 
p300 (NM-1) ThermoFischer Scientific, Germering, Germany 
PARP-1 (Ab-2) Millipore, Darmstadt, Germany 
Phospho-Histone H2A.x (Ser139) New England Biolabs, Frankfurt (Main), Germany 
β-Catenin (H-102) Santa Cruz Biotechnology, Heidelberg, Germany 
Table 2.5: Secondary antibodies 
Antibody (secondary) Provider 
Alexa Fluor 488, Goat-Anti-Mouse 
IgG (H+L) 
Molecular Probes, Eugene, USA 
Alexa Fluor 488, Goat-Anti-Rabbit 
IgG (H+L) 
Molecular Probes, Eugene, USA 
HRP, Goat-Anti-Mouse IgG Santa Cruz Biotechnology, Heidelberg, Germany 
HRP, Goat-Anti-Mouse IgG1 Biozol Diagnostica, Eching, Germany 
HRP, Goat-Anti-Rabbit IgG (H+L) Bio-Rad Laboratories, Munich, Germany 
IRDye 680 LT Goat-Anti-Mouse Li-Cor Biosciences, Bad Homburg, Germany 
IRDye 800 Goat-Anti-Mouse IgG 
(H+L) 
Rockland Immunochemicals, Limerick, USA 
 Cell culture and general lab equipment 2.1.6
Table 2.6: Cell culture and general lab equipment 
Name Provider 
Culture flasks, plates Sarstedt, Nuembrecht, Germany 
Eppendorf Safe Lock Tubes Eppendorf, Hamburg, Germany 
FACS tubes Sarstedt, Nuembrecht, Germany 
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Name Provider 
Falcons, dishes TPP, Trasadingen, Switzerland 
Haake W19, water bath Thermo Haake, Karlsruhe, Germany 
HeracellTM 150, CO2 Incubator ThermoFischer Scientific, Germering, Germany 
HerasafeTM KS, biological safety 
cabinets 
ThermoFischer Scientific, Germering, Germany 
HLC HBT 130, thermo block Biometra, Goettingen, Germany 
ibidiTM µ-Slide Chemotaxis ibidi, Munich, Germany 
ibidiTM μ-Slide 8 Well ibidi, Munich, Germany 
Mikro 22R, centrifuge Hettich, Tuttlingen, Germany 
NanoDrop 1000 Spectrophotometer Peqlab, Wilmigton, USA 
Orion II Microplate Luminometer Titertek-Berthold, Pforzheim, Germany 
SunriseTM Microplate Absorbance 
Reader 
Tecan, Maennedorf, Austria 
Vi-CELLTM RX Cell Viability Analyzer Beckman Coulter, Fullerton, USA 
VXR Vibrax®, shaker IKA®-Werke, Staufen, Germany 
2.2 Technical equipment  
Table 2.7: Technical equipment 
Name Provider 
Atomic Force Microscope (AFM) 
NanoWizard® 4 
JPK Instruments, Berlin, Germany 
Axiovert 25  Zeiss, Jena, Germany 
Canon EOS 450C camera Canon, Krefeld, Germany 
Cantilever MLCT-E/MLCT-C Bruker AFM Probes, Camarillo, USA 
ChemiDocTM Touch Imaging System Bio-Rad Laboratories, Munich, Germany 
FACSCantoTM II BD Biosiences, Heidelberg, Germany 
Heating system Okolab, Pozzuoli, Italy 
Heating system, multi-well plates ibidi, Martinsried, Germany 
Heating system, universal fit ibidi, Martinsried, Germany 
Inverted microscope Eclipse Ti Nikon, Duesseldorf, Germany 
Leica TCS SP8 SMD Leica Microsystem, Wetzlar, Germany 
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Name Provider 
Li-Cor Odyssey® Infrared Imaging 
System 
Li-Cor Biotechnology, Bad Homburg, Germany 
LSM 510 Meta  Zeiss, Jena, Germany 
Olympus BX41 microscope Olympus, Center Valley, USA 
QuantStudio 3 Real-Time PCR 
System 
ThermoFischer Scientific Germering, Germany 
2.3 Cell culture 
 Cultivation of cell lines 2.3.1
The human mammary carcinoma cell lines MDA-MB-231, SKBR3 and SKOV3 were 
purchased from Cell Lines Service (Eppelheim, Germany) and were cultivated in DMEM 
high glucose or RPMI 1640 (in case of SKOV3 cell line) with 1 % penicillin/streptomycin 
(1.5 mM) and 10 % FCS. The bladder carcinoma cell line T24 was maintained in McCoy’s 
medium supplemented with 1 % penicillin/streptomycin (1.5 mM) and 10 % FCS, and was 
kindly provided by Dr. Barbara Mayer (Department of Surgery, LMU Munich, Germany) 
and authenticated by the DSMZ (Braunschweig, Germany). Stable transfected 
HeLa_ssHRP cells were a kind gift from Dr. von Blume (Max Planck Institute of 
Biochemistry, Martinsried, Germany) and were cultivated in DMEM high glucose with 1 % 
penicillin/streptomycin (1.5 mM) and 10 % FCS. HUVECs were purchased from Promocell 
(Heidelberg, Germany) and maintained in endothelial cell growth medium (ECGM) with 
4.7 % supplement mix, 1 % penicillin/streptomycin (1.5 mM), 250 μg/ml amphotericin B 
and 10 % FCS. All cells were cultivated in an incubator with constant humidity of 37°C and 
5 % CO2. Breast cancer cells were passaged twice or thrice weekly in a ratio of 1:5 to 1:10. 
Cells were washed with prewarmed PBS and detached with trypsin/EDTA (T/E). Further, 
cells were resuspended with culture medium and, if necessary counted with Vi-CELLTM RX 
and seeded in cell culture dishes. 
PBS (pH 7.4) NaCl 123.2 mM, Na2HPO4 10.4 mM, KH2PO4 3.2 mM in H2O 
T/E Trypsin 0.05 %, EDTA 0.2 % in PBS 
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 Freezing and thawing of cells 2.3.2
The cell lines were frozen at -20°C for 1-2 hours afterwards transferred to -80°C overnight 
(o/n) and stored in cryovials in liquid nitrogen within culture medium supplemented with 
20 % FCS, 1 % penicillin/streptomycin and 10 % DMSO. For re-cultivation, they were 
thawed in 37°C water bath, transferred into 5 ml of warmed media, and seeded into a 
25 cm2 flask. 2-3 days later, the cells were transferred into a 75 cm2 flask and grown for 
three days before used for experiments. 
2.4 Proliferation and viability 
 Proliferation assay 2.4.1
Proliferation assay was performed in 96-well plates with a concentration of 
5x 103 cells/well. Cells were seeded o/n and treated for 72 h with the indicated 
concentrations of compounds. A few additional seeded wells with untreated cells were 
measured for day zero control. The cells were fixed and stained, after a washing step with 
PBS, with crystal violet/methanol. After washing out crystal violet with ethanol/Na-
citrate, the absorption was determined by microplate reader at 540 nm.  
Crystal violet/methanol 0.5 % crystal violet (w/v), 20 % methanol (v/v) 
Ethanol/Na-citrate 50 % ethanol (v/v), 50 % 0.1 M Na-citrat (w/v) 
 CellTiter-Blue (CTB) viability assay 2.4.2
To analyze the viability of cancer cells, they were seeded in 96-well plates o/n. The cells 
were treated with the indicated compounds for 72 h or measured for day zero control. 
The viability of cells was determined by incubation with CellTiter-Blue® (CTB) reagent for 
2 h. Measurement was performed with microplate reader. 
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2.5 Flow cytometry measurement 
 Propidium iodide (PI) and Yo-Pro-1 (YP) exclusion assay 2.5.1
The cancer cells were cultivated in twelve-well plates with a concentration of 
4x 104 cells/well, were stimulated with the study compounds and harvested by 
trypsination in FACS tubes. After a washing step with PBS, the cells were exposed to a 
solution of propidium iodide (PI, 5 µg/ml) or Yo-Pro-1 (YP, 100 nM) in PBS. Subsequently, 
cells were analyzed immediately by flow cytometry using FACSCantoTM II.  
Dying cells showed increased cell permeability and higher absorption of PI or YP. The 
fluorescence cytometer showed an increased fluorescence signal at 580 nm (PI) or 
509 nm (YP) for dead cells after excited with the 488 nm spectral line of an argon-ion 
laser. Therefore, cells with a fivefold higher fluorescence signal were considered as PI or 
YP positive cells. 
 Nicoletti assay and cell cycle analysis 2.5.2
Cells were cultivated, harvested and washed with PBS as explained in 2.5.1. After the 
treatment and harvest, cells were exposed to the hypotonic fluorochrome solution (HFS), 
for 30 min. Next, the DNA of cells was stained with PI by permeabilization with 
Triton X-100. The percentage of cells in each cell cycle phase could be calculated by a 
histogram, which depicted the amount of living cells in S, G1 and G2 phase peaks. The DNA 
of dead cells showed fragmentation and could be detected in front of G1 peak (subG1). 
The apoptosis rate was calculated by percentage subG1 population.54 
HFS Triton X-100 0.1 % (v/v), sodium citrate 0.1 % (w/v), propidium iodide 50 µg/ml 
2.6 In vivo xenograft mouse model 
 Animal experiment 2.6.1
5x 106 MDA-MB-231 cells were injected subcutaneously into the flank of each SCID mouse 
(C.B-17/IcrHan®Hsd-Prkdcscid, Harlan Laboratories, USA). 40 mice were divided into four 
treatment groups (ten mice per group): solvent (DMSO) control group, two single groups 
treated intravenously either with doxorubicin (Doxo) 1.5 mg/kg body weight (once a 
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week) or with chondramide B (ChB) 0.6 mg/kg body weight (thrice a week) and a 
combination of both. During the treatment the weight of mice was measured and the 
tumor volume was calculated with the formula V = a·b2/2 every second day. After 36 days 
the mice were sacrificed and tumor growth and weight were determined. All animal 
procedures were carried out according to the guidelines of the German law of protection 
of animal life and approved and controlled by the local ethics committee. The animal 
experiment was performed by Dr. Rebekka Kubisch and Johanna Busse in the laboratory 
of Prof. Dr. Ernst Wagner (Pharmaceutical Biotechnology, LMU Munich, Germany).  
 Histological tumor staining 2.6.2
Tumors were removed, fixed in formalin and embedded in paraffin blocks. Sections were 
prepared and stained with anti-Ki67 antibody and visualized with the VECTASTAIN® ABC 
Kit according to the manufacturer's instructions. Four tissues per treatment group were 
analyzed and images were taken on the Olympus BX41 microscope. The Ki67 positive cells 
were counted with ImageJ 1.51f and normalized to total number of cells. 
2.7 Metastasis assays 
 Wound healing assay 2.7.1
The wound healing or scratch assay was performed with confluent cell layers. Cells were 
pretreated for 72 h with the indicated compound concentrations, seeded into 96-well 
plates and incubated for minimum five hours at 37°C. Scratch was executed with a tip and 
after 14 h migration cells were stained with crystal violet/methanol. Pictures of the 
scratch were taken with the Inverted microscope Eclipse Ti. 
 Boyden chamber assay 2.7.2
With Boyden chamber migration assay the migration through restricted pores towards an 
FCS gradient could be determined. The cells were pre-stimulated for 72 h with the 
indicated compound concentration and 2x 104 cells were seeded without compound in 
FCS negative medium in the upper compartment of the chamber. The lower 
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compartment was filled with medium containing 10 % FCS to generate an FCS gradient. 
After migration of 20 h, cells were fixed and stained with crystal violet/methanol. 
Remaining cells in the upper compartment were removed with q-tips and pictures of the 
bottom side of membrane were taken with the Axiovert 25 microscope and Canon EOS 
450C camera. The amount of migrated cells was analyzed with ImageJ 1.51f. 
 Adhesion assay 2.7.3
The adhesion assay was performed with pre-treated cells in 96-well plates. A 
concentration of 4x 104 cells/well were seeded in collagen G coated wells and allowed to 
adhere for 90 min. Cells were stained with crystal violet/methanol and imaged with 
Axiovert 25 microscope and adhering cells were counted. 
 Chemotaxis assay 2.7.4
With the chemotaxis assay, migration of cells along a FCS gradient without environmental 
restriction could be detected. Cells were pre-treated with the indicated compound 
concentration and seeded into ibidiTM µ-Slide Chemotaxis, collagen IV coated chamber in 
compound free medium. After the cells had attached to the chamber slide, the channel 
was washed with medium without FCS and a gradient was generated by filling one 
reservoir with FCS negative medium and the other with 10 % FCS medium. For negative 
control 10 % FCS was filled in both reservoirs, which generates an environment of 
undirected migration. Images were taken every ten minutes and the indicated migration 
parameters were calculated by the chemotaxis and migration tool Qt Open Source Edition 
version 4.3.2. 
 Three dimensional (3D) collagen I gel migration 2.7.5
Rat tail collagen I gels were prepared according to the manufacturer’s protocol. Briefly, 
gels with a concentration of 2 mg/ml were mixed on ice with 0.25x 106 cell/mixture. 
Collagen I was added at the end and immediately pipetted into ibidiTM µ-Slide 
Chemotaxis. For gelation, the gel was left 15 min on ice, before incubated for a minimum 
of 1 h at 37°C, 5 % CO2 in incubator. The chemotaxis reservoirs were filled with medium 
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with or without FCS to create an FCS gradient. Life cell images were taken by Inverted 
microscope Eclipse Ti. 
Collagen I gel (150 µl) RPMI 1640 10x (10 µl), NaOH 1 M (3 µl), H2O (57.2 µl), NaHCO3 
7.5 % (2.5 µl), RPMI 1640 1x (25 µl), Rat tail collagen I 11 mg/ml 
(27.3 µl), SKOV3 cells 0.25x 106 (25 µl) 
2.8 HRP secretion assay 
HeLa_ssHRP (signal sequence horseradish peroxidase) cells were seeded and pre-
stimulated as described before. After an indicated stimulation period, the medium was 
removed and the cells were washed five times with fresh medium. Further, 300 µl of 
fresh medium with or without compound were added. Brefeldin A was used as a positive 
control. The secretion was allowed in an incubator over 4 h, before harvesting the cells. 
The medium was collected as secretion probe, while cells were trypsinated and collected 
by centrifugation. The cell pellets were lysed with 0.5 % Triton-X 100 in PBS on ice for 
20 min. After an additional centrifugation at 4°C, 14000x g for 20 min, supernatants and 
pellet fraction were applied to a 96-well plate. The HRP substrate 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) was added to probes and the absorbance was read 
out at 405 nm with Tecan Microplate Reader. The supernatant signal was normalized to 
the pellet signal. 
2.9 Microscopy 
 Confocal laser scanning microscopy 2.9.1
The cell lines were seeded in ibidiTM μ-Slides, cultivated o/n and treated with different 
compounds for indicated time points. The cells were permeabilized with Triton X-100 
0.1 % (v/v), blocked with BSA 1 % or 5 % and stained first with a specific primary antibody 
(Table 2.8). The primary antibodies were diluted 1:400 or 1:500 with BSA 1 % and 
incubated for 1 h at RT or o/n at 4°C. After two washing steps with PBS+, secondary 
fluorescence antibodies (Table 2.9), diluted 1:1000 in BSA 1 %, were incubated at RT for 
1 h. The fluorescence signal was optimized by sealing cells with mounting medium 
FluorSaveTM reagent and a cover slip. 
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PBS+ Ca2+/Mg2+ (pH 7.4) NaCl 136.9 mM, KCl 2.7 mM, Na2HPO4 8.1 mM, KH2PO4 3.2 mM, CaCl2 
x 2H2O 0.7 mM, MgCl2 x 6H2O 0.5 mM 
Table 2.8: Primary antibody for fluorescence staining 
Antigen Source Dilution 
GM130 (D6B1) Rabbit 1:500 
Myo18A Rabbit 1:400 
NFAT5 Mouse 1:500 
β-Catenin (H-102) Rabbit 1:500 
p300 Mouse 1:400 
Table 2.9: Secondary antibody for fluorescence staining 
Fluorescence labeled Antibody Dilution 
Alexa Fluor 488, Goat-Anti-Rabbit IgG (H+L) 1:1000 
Alexa Fluor 488, Goat-Anti-Mouse IgG (H+L) 1:1000 
 Life cell imaging 2.9.2
The Inverted microscope Eclipse Ti was used for the imaging of migrating cells during life 
cell experiments. Pictures were obtained using the 10x phase contrast objective and 
charge coupled device camera every ten minutes over 20 h. The slide was incubated at 
37°C, 5 % CO2, humidity of 80 % during measurements. Images were evaluated with 
ImageJ 1.51f. 
 Atomic force microscopy 2.9.3
Cells were seeded into 34 mm dishes and stimulated for 72 h with the indicated 
concentrations of compound. The stiffness of total cell surface and the specific nucleus 
stiffness was measured with the atomic force microscope (AFM) NanoWizard® 4 and 
subsequently analyzed by Daniel Ruediger. Briefly, cantilevers (MLCT-E: k=0.1 N/m, 
f=38 kHz; MLCT-C: k=0.01 N/m; f=7 kHz; silicon nitride; front angle 15±2.5°; quadratic 
pyramid tip shape) were calibrated with contact-free method and used for measurements 
in the contact mode. Total cellular stiffness was determined by a force map with an area 
of 80x80 µm, whereas, stiffness of the nucleus was measured by single force curves. For 
both measurements the velocity was 2 µm/s and the set point was appointed to 1 nN. 
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The data were analyzed with the NanoWizard® Data Processing software version 6.0.50 
and the stiffness was calculated according the Hertzian contact model (young’s modulus). 
2.10 DNA damage response measurements 
 Comet assay 2.10.1
SKOV3 cells were seeded and treated as described before. 20 µl cells were trypsinated 
and mixed with 20 µl 37°C prewarmed 1.4 % agarose, low gelling temperature with 
GelRedTM to an agarose concentration of 0.7 %. 30 µl of cell-agarose mix were pipetted on 
pre-coated glass slides and solidified on ice for 10 min. The slides were lysed in lysis 
buffer o/n at 4°C or 2 h in the dark. Afterwards, the slides were washed with PBS and 
transferred to the electrophoresis tank filled with electrophoresis buffer. Further, the 
electrophoresis was proceeded 10 min at 300 mA (25-30 V). The slides were washed again 
with PBS and incubated in 70 % ethanol for 1 h and further air-dried o/n at RT. The 
images were taken with a confocal microscope after covering the slides with FluorSaveTM 
and a cover slip. Tail moment (TM) was quantified with the ImageJ 1.51f plugin 
OpenComet 1.3 with the following formula: TM = tail length x tail DNA %. 
Lysis buffer NaCl 2.5 M, EDTA 0.1 M, Tris 10 mM, Triton X-100 1 %, pH 10 in H2O 
Electrophoresis buffer NaCl 0.3 M, EDTA 1 mM, pH 13 in H2O 
 Golgi area 2.10.2
SKOV3 cells were seeded and treated as described for confocal laser scanning microscopy 
in ibidiTM μ-Slides. Cells were stained with GM130 antibody (1:400 in 5 % BSA), fixed and 
imaged with an LSM 510 Meta microscope. The Golgi area was analyzed by calculation of 
Golgi signal normalized to the cell number with ImageJ 1.51f.  
2.11 Quantitative real-time PCR analysis 
Cells were cultivated in six-well plates and stimulated as described before. Total mRNA 
was isolated by Qiagen RNeasy® Mini Kit according to the manufacturer’s protocol. mRNA 
level was determined with the NanoDrop 1000 Spectrophotometer and 1.5 to 2.0 µg 
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mRNA were transcribed into complementary DNA (cDNA) by High-Capacity cDNA reverse 
transcriptase. Quantitative real-time PCR was performed in QuantStudio 3 Real-Time PCR 
System with SYBR® Green Master Mix, indicated forward and reverse primer, and 
template cDNA. GAPDH was used as housekeeping gene. All primers were purchased 
from Metabion, Planegg, Germany. 
Table 2.10: qRT-PCR primer 
mRNA Forward Reverse 
GAPDH 5'-ACG GGA AGC TTG TCA TCA AT-3' 5'-CAT CGC CCC ACT TGA TTT T-3' 
EP300 5'-CAT GGG TAT GAA CCC ACC TC-3' 5'-GTG GAG CCA TGT TCA AAG GT-3' 
CYR61 5'-ACC CTT CTC CAC TTG ACC AG-3' 5'-CTT GGC GCA GAC CTT ACA G-3' 
2.12 Western blot 
Western blot analysis was performed to determine protein levels of whole cell lysates or 
cell fractions. The cells were cultivated as described in 2.3.1 and stimulated with 
compounds for the indicated time points.  
 Total cell lysate 2.12.1
The detached cells from three wells were pooled in culture medium and centrifuged for 
10 min at 1500 rpm at 4°C. The supernatant was discarded and cells were washed with 
500 µl PBS and transferred to Eppendorf tubes. After additional centrifugation the 
supernatant was again discarded and 85 µl of lysis buffer were added. Samples were 
frozen o/n at -20°C and further centrifuged again at 10000x g, 4°C for 10 min. 80 µl of 
supernatant (cell lysates) were collected for SDS PAGE with 20 µl 5x sample buffer and 
boiled 95°C for 5 min. 5 µl of supernatant were diluted with 45 µl distilled water and were 
used for Bradford protein quantification. Protein amounts were determined with Roti®-
Quant as described before by Bradford.55 10 µl of diluted lysates or BSA standard stock 
solution and 190 µl of 1x Bradford solutions were pipetted in a flat-bottom 96-well plate. 
Samples were incubated with Bradford reagent and measured in ELISA reader. 
Concentration of samples was adapted with 1x SDS sample buffer. SDS gels were 
prepared for separating gel with a concentration of 7.5 % to 12 % and stacking gel in glass 
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plates. After polymerization, gels were stored at 8°C. For the electrophoresis, 20-30 ng of 
protein samples and diluted Page Ruler were loaded on the prepared gel. The chamber 
was filled with Epho buffer and the following running program was adjusted: P1.1: 100 V, 
500 mA, 150 W for 21 min and P1.2: 200 V, 500 mA, 150 W for 38 min. Usually, stain-free 
gels were prepared. Herein, the tryptophan in proteins undergo a reaction by UV light 
exposure and displayed visualizable fluorescence signal, therefore, total protein amount 
could be detected.56 The proteins were transferred in 1 h 20 min from the gel to a 
nitrocellulose or PVDF membrane, which were activated in tank buffer. Afterwards, the 
membrane was blocked with 5 % BSA in TBS-T for 1 h at RT. Finally, the proteins on the 
membranes were incubated with primary antibody o/n at 4°C with the following 
solutions: 
Table 2.11: Dilution of primary antibody 
Antigen Source Dilution Solvents 
Actin (C4) Mouse IgG1 1:1000 Blotto 1 % 
GAPDH (7B) Mouse 1:1000 Blotto 1 % 
p300 (NM-1) Mouse IgG1 1:1000 BSA 5 % 
PARP-1 (Ab-2) Mouse IgG1 1:1000 BSA 5 % 
phospho-Histone H2A.x (Ser139) Rabbit 1:1000 BSA 5 % 
Myo18A Rabbit 1:1000 BSA 5 % 
The membranes were incubated with secondary HRP-conjugated antibodies or Li-Cor 
fluorescence antibodies after three washing steps with TBS-T for 1 h at RT. The following 
antibody solutions were used: 
Table 2.12: Dilution of secondary antibody 
Secondary Antibody Dilution Solvents 
HRP, Goat-Anti-Mouse IgG 1:10000 BSA 1 % 
HRP, Goat-Anti-Mouse IgG1 1:10000 BSA 1 % 
HRP, Goat-Anti-Rabbit IgG (H+L) 1:10000 BSA 1 % 
IRDye 680 LT Goat-Anti-Mouse 1:10000 Blotto 1 % 
IRDye 800 Goat-Anti-Mouse IgG (H+L) 1:10000 Blotto 1 % 
The membranes were incubated either with HRP Homemade ECL solution, which 
activated the turnover of luminol by HRP and lead to a detectable chemiluminescence 
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signal by ChemiDoc™ Touch Imaging System, or were directly measured with Li-Cor 
Odyssey® Infrared Imaging System, if incubated with the IRDye antibodies. The band 
intensity of detected Western blot was normalized to the total protein amount (stain-
free) or GAPDH as loading control. 
Phospho-lysis buffer NaCl 137 mM, Glycerol 10 %, Na4P2O7 x 10H2O 2 mM, Na2EDTA 2 mM, 
Tris-Base 20 mM, Triton-X 100 1 %, Na2-glycerophosphate x 5H2O 
20 mM, NaF 10 mM, PMSF 1 mM, CompleteTM 25x 4 %, Na3VO4 2 mM 
5x SDS sample buffer Tris HCl (pH 6.8) 3.13 M, Glycerol 10 %, SDS 20 %, DTT 16 %,  
Pyronin Y 5 % in H2O; 1x SDS sample buffer were diluted in H2O 
Separating gel 30 % Rotiphorese® 5 ml, Tris HCl 1.5 M (pH 8.8) 3.75 ml, SDS 10 % 
150 µl, H2O 6.1 ml, 0.5 % 2,2,2-trichloroethanol, TEMED 15 µl, APS 
10 % 75 µl 
Stacking gel 30 % Rotiphorese® 1.275 ml, Tris HCl 1.25 M (pH 6.8) 750 µl, SDS 10 % 
75 µl, H2O 5.25 ml, TEMED 15 µl, APS 10 % 75 µl 
5x Electrophoresis 
buffer (Epho)  
Tris-base 24.8 mM, Glycine 191.8 mM, SDS 3.5 mM in H2O;  
1x Epho diluted 1:5 in H2O 
5x Tank buffer Tris-base 25 mM, Glycine 192 mM in H2O 
TBS-T (pH 8.0) Tris HCl 24.8 mM, NaCl 190 mM, Tween 20 0.2 % in H2O 
HRP Homemade ECL Luminol 1.25 mM, Cumaric acid 0.2 mM, Tris-base HCl (pH 8.5) 0.1 M, 
H2O2 0.009 % in H2O 
 Cytosolic-cytoskeletal fractionation 2.12.2
The cytosolic-cytoskeletal fractionation was modified according to Zeidman et al.57 Cells 
were centrifuged after trypsination at 1500 rpm for 10 min, 4°C. Supernatant was 
discarded and the cells were lysed for 30 min with phospho-lysis buffer (see 2.12.1) 
supplemented with iodoacetic acid 4 mM. The cells were centrifuged at 300x g to 
pelletize debris and nuclei. Supernatant was further centrifuged at 14000 rpm, which 
collected the cytoskeletal fraction as pellet and the cytosolic fraction in supernatant. 
Cytoskeletal fraction was collected in PBS supplemented with PMSF (1 mM), Na3VO4 
(2 mM), CompleteTM (25x 1 %) and iodoacetic acid (4 mM). Bradford protein 
quantification and the protein detection were performed as described in 2.12.1. 
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2.13 Reporter gene assay 
Cells were seeded in 24-well plates and transfected five hours later with reporter gene 
plasmid M50 Super 8x TOPFlash or M51 Super 8x FOPFlash (TOPFlash mutant) (#12456 
and #12457, Addgene, Cambridge, USA) and one-tenth of pGL4.74[hRluc/TK] plasmid 
(Promega, Mannheim, Germany) for 72 h. The day after transfection cells were 
stimulated with compound. LiCl (40 mM) was used for TCF/Lef1 promoter activation by 
disinhibiting β-catenin. The luciferase intensity was measured 56 h after treatment with 
Promega Dual-Luciferase kit according to manufacturer’s protocol. Briefly, cells were 
washed with PBS, lysed with 50 µl of 1x passive lysis buffer (Promega kit), and plates were 
frozen o/n at -80°C. 20 µl of the lysed unfrozen cells were transferred to luminometer 
plates. 100 µl Luciferase Assay Reagent II (Promega kit) were added in each well to 
measure the firefly luciferase activity and afterwards 100 µl Stop & Glo (Promega kit) 
reagent were added to stop the firefly luciferase activity and measure the activity of 
renilla luciferase. The chemiluminescence signal was determined using the Orion II 
Microplate Luminometer. 
2.14 Calculations and statistics 
 Calculation of specific cell death and Bliss synergism 2.14.1
Specific cell death (and apoptosis) was calculated by the following formula: 
ݏ݌݁ܿ. ݈݈ܿ݁ ݀݁ܽݐ݄ ൌ ݈݈ܿ݁ ݀݁ܽݐ݄ ሾ%, ܿ݋݉݌ሿ െ ݈݈ܿ݁ ݀݁ܽݐ݄ ሾ%, ܥݐݎ݈ሿ100 െ ݈݈ܿ݁ ݀݁ܽݐ݄ ሾ%, ܥݐݎ݈ሿሻ ∗ 100 
Formula 2.1: Calculation of specific cell death (spec. cell death). comp: compound, Ctrl: control.58 
 
Synergy effect of compounds was calculated by using the formula of Bliss synergism. The 
value of Bliss synergism was calculated as following: 
ܸ݈ܽݑ݁ ൌ ܥሾܿ݋ܾ݉݅ ݐݎ݁ܽݐሿሺܥሾܿ݋݉݌ ܣሿ ൅ ܥሾܿ݋݉݌ ܤሿሻ െ ሺܥሾܿ݋݉݌ ܣሿ ∗ ܥሾܿ݋݉݌ ܤሿሻ 
Formula 2.2: Calculation of Bliss synergism. C: cytotoxic fraction, combi treat: combination 
treatment, comp: compound.59 
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Values > 1.05 indicated Bliss synergism, values from 0.95 to 1.05 indicated additivity and 
values < 0.95 indicated Bliss antagonism. 
 Proteome data 2.14.2
The proteome data was analyzed using Perseus MaxQuant software. The detected 
proteins were grouped into ten clusters. The cluster with down-regulated proteins after 
stimulation for 56 h was depicted in a plot with the statistic software R (R version 3.3.2). 
GOBPs (Gene Ontology and Biological Pathways) and KEGG (Kyoto Encyclopedia of Genes 
and Genomes) pathways were plotted with a threshold of FDR < 0.5.60 Pathway with 
FDR < 0.2 (plotted in orange) and the highest enrichment values (enrichment > 2) were 
depicted in red with annotations. 
 Statistics 2.14.3
The experiments were done in triplicates and performed three times, if not otherwise 
noted. One-way ANOVA test with relevant posttest (Dunnett’s Multiple Comparisons or 
Bonferroni’s Multiple Comparison Test) or paired two tailed t-test were used to assess the 
significance between treatment groups or pairs. The statistical analysis was conducted 
with GraphPad Prism 5 and Microsoft Excel. 
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3 RESULTS 
3.1 Targeting the DNA damage response in cancer via the actin 
cytoskeleton  
Actin binding agents were supposed to induce strong side effects in application of higher 
dosage. The combination of compounds such as chondramide B (ChB) with common 
chemotherapeutics could circumvent such limiting factors. For instance, the DNA 
damaging agent doxorubicin (Doxo) was used for decades in the clinic in combination or 
triple therapy.8 
 Combination of doxorubicin and chondramide B reduced tumor growth 3.1.1
in vivo 
Based on this knowledge and on preliminary results of my master thesis, a xenograft 
in vivo trial with immunodeficient SCID mice was performed in order to elucidate the 
impact of Doxo and ChB combination treatment on tumor formation. The animal 
experiment was conducted as described in 2.6.  
The combination treatment of mice inhibited growth of MDA-MB-231 tumors after 
36 days (Figure 3.1 A). Here, the tumor volume of single or control treated mice was 211 
to 242 mm3, whereas the combination treated group showed a reduction by half of the 
tumor volume to about 122 mm3. Further, the number of Ki67 positive cells in tumor 
sections (Figure 3.1 B) was decreased in the combination treatment (9 %) in comparison 
to control and ChB (29 %). Those results indicated an inhibition of proliferation of 
combination treated tumors in mice. The observed health conditions of combination 
treated mice, represented by the body weight (Figure 3.1 C), were unaffected by 
combination treatment of ChB and Doxo and showed conditions comparable to the 
control group. In summary, the combination treatment achieved growth inhibitory effects 
on xenograft tumors and was well tolerated by tested mice. 
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Figure 3.1: Combination treatment (+/+) of doxorubicin (Doxo) and chondramide B (ChB) was 
tolerable and inhibited tumor growth and proliferation in vivo. MDA-MB-231 cells were 
ectopically injected into in the flank of SCID mice. DMSO was used as solvent control (Ctrl); 
doxorubicin (Doxo) 3.5 mg/kg body weight (once a week), chondramide (ChB) 0.6 mg/kg body 
weight (thrice a week) and a combination of ChB and Doxo. A: 8-10 mice per group were treated 
with single, combination or solvent. B: Proliferation marker Ki67 (red) staining of paraffin 
embedded tumor sections. One representative staining per treatment group is shown with a 40x 
magnification and quantification, n=4. C: Progression of body weight over the treatment, n=8-19. 
TI, tumor injection. One-Way ANOVA/Bonferroni’s Multiple Comparison Test, *p < 0.05.  
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 Cell death was induced in different cancer cell lines 3.1.2
In line with the in vivo experiment, we were interested to elucidate the exact mechanism 
behind this prominent combination treatment effect of inhibiting tumor growth (Figure 
3.1). Therefore, in vitro experiments with different cell lines were conducted. First, we 
tested different concentrations of chondramide (ChB) and doxorubicin (Doxo) in CTB 
viability assays, and observed the highest reduction of viability with the combination of 
Doxo 250 nM and ChB 75 nM or 100 nM, with concurrent effects by ChB single treatment. 
Furthermore, the specific cell death and apoptosis induction after combination treatment 
with ChB and Doxo were analyzed. The amount of dying cells was determined dependent 
on the cell line by YP exclusion or Nicoletti assay. Figure 3.2 depicts the significantly 
increased induction of specific cell death in MDA-MB-231 cells (B) and specific apoptosis 
of T24 cells (C) in combination treatment of ChB and Doxo. Additionally, the PARP-1 
cleavage was significantly increased after the combination treatment (D). The tested 
compounds, ChB and Doxo, demonstrated synergistic effects in combination treatment 
indicated by the Bliss value of 1.56 for MDA-MB-231 and 1.82 for T24 cells on cell death 
induction. These results pointed out the reproducibility of the synergistic effects in vitro 
of actin binding compound ChB and DNA damaging agent Doxo. 
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Figure 3.2: Viability, cell death and apoptosis induction after 72 h (T24) and 48 h (MDA-MB-231)
combination treatment with chondramide B (ChB) and doxorubicin (Doxo). A: CTB viability assay 
after 72 h treatment with the indicated concentrations of ChB and Doxo, n=3-4. B and C: Specific 
cell death and apoptosis analysis of MDA-MB-231 and T24 cells. D: Western blot analysis of 
apoptosis markers PARP-1 in MDA-MB-231 normalized to total protein amount (stain-free), n=3.
ns, not significant. One-Way ANOVA/Bonferroni’s Multiple Comparison Test, *p < 0.05,  
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 The combination treatment increased DNA damage 3.1.3
Following the confirmation of functional effects in vivo and in vitro, we were interested in 
the synergistic mode of action of both compounds. Doxo induces DNA double strand 
breaks and is known for its DNA damaging properties, while a link between actin binding 
agents such as ChB and DNA damage repair mechanisms has not been clarified yet. To 
evaluate the synergistic effects of ChB and Doxo, the amount of phosphorylation of 
histone 2A.x (γH2A.x), which is recruited to the DNA double strand breaks, was tested 
(Figure 3.3 A). γH2A.x was increased in Doxo single treated cells, but even more after the 
combination with ChB. The treatment with ChB showed no phosphorylated H2A.x. Aside 
from increased γH2A.x amounts the Comet assay was performed. Thus, the DNA double 
strand break induction due to combination treatment was analyzed (Figure 3.3 B). The 
DNA damage was significantly increased by ChB and Doxo treatment to 1.7-fold as 
compared with Doxo single treatment, indicated by higher values of tail moment. 
 
Figure 3.3: The combination treatment in cancer cell lines showed increased DNA damage. Cells
were treated for 3 h with the indicated concentrations of chondramide B (ChB) and doxorubicin
(Doxo). A: Western blot analysis and the quantification of DNA damage marker γH2A.x in treated 
MDA-MB-231 cells. B: Detection of DNA double strand breaks in treated T24 cells with Comet 
assay. The quantification of tail moment and one representative image per treatment is shown
with a magnification of 20x, n=3. ns, not significant. One-Way ANOVA/Bonferroni’s Multiple 
Comparison Test, *p < 0.05. 
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 DNA damage induced Golgi dispersal was altered after ChB treatment 3.1.4
In 2014, Farber-Katz et al. published the connection of DNA damage response (DDR) 
mechanism and alteration of Golgi complex.43 As they stated the dispersal of Golgi 
complex as a significant response to DNA damage, we measured the Golgi area after Doxo 
and ChB single and in combination treatment. The confocal microscopy staining of Doxo 
single treated MDA-MB-231 cells showed significantly increased Golgi area up to 2.5-fold 
change to control (Figure 3.4). The combination treatment with ChB displayed a reduction 
of Golgi area comparable to the control or ChB single treatment, which suggested no 
considerable DDR induction (Figure 3.4). This result indicated the inhibition of DNA 
damage repair response by ChB after DNA damage induction by Doxo. 
 
Figure 3.4: The combination treatment showed interrupted Golgi dispersal. Immunostaining of 
MDA-MB-231 cells treated with chondramide B (ChB), doxorubicin (Doxo) or a combination of 
both compounds for 48 h. Stained for Golgi complex (GM130, green), actin (rhodamine-phalloidin, 
red) and nucleus (Hoechst 33342, blue) and the quantification of Golgi area. One representative 
image per treatment is shown, n=3. White bars indicate 10 µm. One-Way ANOVA/Bonferroni’s 
Multiple Comparison Test, *p < 0.05. 
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 ChB interrupted the signaling cascade by myosin 18A trapping 3.1.5
The unconventional myosin 18A (Myo18A) is important for the Golgi dependent DNA 
damage response (DDR) followed by increased survival.43 Concurrently, the actin 
polymerizing compound, ChB, is known to induce actin agglomerates and was verified to 
trap and thus, to inhibit the function of pro-survival proteins.33 Therefore the localization 
of Myo18A relating to actin agglomerates was determined (Figure 3.5). The confocal 
microscopy pictures displayed a prominent co-localization of Myo18A in actin 
agglomerates after ChB single treatment and in the combination with Doxo (Figure 3.5 A). 
Furthermore, the cytosolic-cytoskeletal fractionation depicted enhanced Myo18A protein 
amount simultaneously with actin in the cytoskeletal fraction (Figure 3.5 B). Those results 
indicated the inhibition of Golgi dispersal via Myo18A trapping due to the induction of 
actin agglomerates. 
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 DNA-PK was crucial for Golgi dispersal cascade and cell survival 3.1.6
DNA-PK is one of the numerous DNA damage activated protein kinases and turned out to 
phosphorylate GOLPH3 followed by Golgi dispersal due to its kinase activity.43 According 
to the results of Farber-Katz et al., DNA-PK activity was inhibited by the specific inhibitor 
NU7026. The combination treatment of NU7026 and Doxo showed an inhibition of Golgi 
dispersal due to the suppression of DDR cascade (Figure 3.6 A). Moreover, the inhibition 
of Golgi dispersal by suppression of DNA-PK indicated the induction of cell death after 
DNA damage triggered by Doxo (Figure 3.6 B). This specific cell death induction showed a 
comparable Bliss synergism value of 1.56 by combination treatment of Doxo and NU7026. 
Based on these results, it could be concluded that the inhibition of DNA-PK activity 
 
Figure 3.5: Combination treatment showed trapping of myosin 18A (Myo18A) in actin 
agglomerates. T24 cells were treated with the indicated concentrations of chondramide B (ChB) 
and doxorubicin (Doxo). A: Immunostaining after 48 h treatment of T24 stained for Myo18A 
(antibody, green), actin (rhodamine-phalloidin, red) and nucleus (Hoechst 33342, blue), n=3.
B: Western blot analysis of the cytosolic-cytoskeletal fractionation of T24 cells after 6 h treatment, 
n=1. One representative image per treatment is shown. White bars indicate 10 µm. 
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indicated the same functional outcome as trapping of Myo18A via actin agglomerates 
after ChB treatment and ended in the induction of cell death in the cancer cell line 
MDA-MB-231. 
 SKBR3 cells were insensitive to combination treatment 3.1.7
The examination of another cancer cell line validated the importance of Golgi response 
after DNA damage. The SKBR3 cell line depicted an altered Golgi localization in control 
cells compared to MDA-MB-231 cells. In control cells the Golgi complex was more spread 
around the nucleus and showed no enhanced Golgi area after Doxo treatment although 
the DNA was damaged even in a lower Doxo concentration, as assessed by the DNA 
damage indicator γH2A.x (Figure 3.7 A and B). Furthermore, DNA damage was not 
increased after combination treatment of ChB and Doxo in SKBR3 cells and showed no 
enhanced cell death induction (Figure 3.7 C). These data suggested the importance of 
 
Figure 3.6: NU7026 inhibited the Golgi dispersal and induced cell death in combination with 
Doxo. MDA-MB-231 cells were treated for 48 h with the indicated concentrations of NU7026 and 
doxorubicin (Doxo). A: Stained for Golgi complex (GM130, green), actin (rhodamine-phalloidin, 
red), and nucleus (Hoechst 33342, blue) with the quantification of Golgi area (bar diagram). One 
representative image per treatment is shown, n=3. B: Specific cell death analysis, n=3. White bars 
indicate 10 µm. One-Way ANOVA/Bonferroni’s Multiple Comparison Test, *p < 0.05. 
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DNA response mechanism based on Golgi dispersal. The synergistic effects of Doxo and 
ChB need the DDR dependent on Golgi dispersal, as it was the case in MDA-MB-231 cells 
and T24 (Figure 3.2, Figure 3.4), to induce higher DNA damage followed by the induction 
of cell death. 
  
 
Figure 3.7: SKBR3 cells showed no induction of cell death due to altered Golgi response. SKBR3 
cells were treated for 48 h with the indicated concentrations of chondramide B (ChB) and 
doxorubicin (Doxo). A: Stained for Golgi complex (GM130, green), actin (rhodamine-phalloidin, 
red), and nucleus (Hoechst 33342, blue) and the quantification of Golgi area (bar diagram). One 
representative image per treatment is shown, n=3. B: Western blot analysis of DNA damage 
marker γH2A.x and loading control GAPDH. C: Specific cell death analysis, n=3. White bars indicate 
10 µm. Golgi dispersal images with SKBR3 and the quantification were conducted by Alisa Krieg. 
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 Combination treatment showed low toxicity levels on non-cancer cells 3.1.8
As mentioned, the side effects induced by Doxo treatment are known to be very 
prominent. Especially the cardiotoxicity limits the clinical use of Doxo, and combination 
compounds with non-additive cardiac effects are needed.49 Therefore, the effect of ChB 
and Doxo was tested in neonatal rat cardiomyocytes (Figure 3.8 A and B). The number of 
cardiomyocytes after combination treatment was still higher (0.48-fold) in comparison to 
the standard in vitro dose of 1000 nM Doxo (0.13-fold), which indicated lower 
cardiotoxicity. In line, the hypertrophy of cardiomyocytes was determined by the 
cardiomyocyte area measured with an α-actinin staining. The treatment of ChB and Doxo 
showed no significantly enhanced cardiomyocyte area and pointed out the negligible side 
effects of the combination treatment. The second examined non-cancer cell type was the 
human umbilical vein endothelial cell (Figure 3.8 C). The investigation of endothelial cells 
showed no induction of apoptosis and underlines a high feasibility of the combination 
treatment for future clinical trials.  
 
Figure 3.8: Clinical investigations with neonatal rat cardiomyocytes and human umbilical vein 
endothelial cells (HUVEC) after combination treatment. Non-cancer cells were treated with the 
indicated concentrations of chondramide B (ChB) and doxorubicin (Doxo). A: Neonatal rat 
cardiomyocytes number after 24 h treatment, 1000 nM Doxo indicates positive control. B: The 
quantification of cardiomyocytes area (α-actinin staining) after 24 h treatment represents an 
indicator for cardiac hypertrophy, n=3. C: Nicoletti assay of HUVECs after 48 h treatment, n=3. ns: 
not significant. One-Way-Anova/Bonferroni’s Multiple Comparison Test, *p < 0.05. Experiments 
were conducted by Dr. Ramanujam (Pharmacology and Toxicology, TU Munich) and Alisa Krieg. 
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3.2 Inhibition of migration by actin binding compound 
miuraenamide A beyond actin hyperpolymerization 
Besides the combination treatment of actin binding compounds with common 
chemotherapeutic drugs, another option is the clinical application of this compound class 
in single low dose treatment. Consequently, the structurally and functionally related 
miuraenamide (Miu) was analyzed in lower treatment concentration concerning the 
migratory inhibition of cancer cells. 
 Low dose Miu treatment slightly affected the cell functions 3.2.1
Miuraenamide A (Miu) is a potent actin hyperpolymerizing compound in higher 
concentrations and shows cytotoxic effects on various cancer cell lines.37 A clinical low 
dose application of compounds is supposed to indicate lower side effects in patients. 
Therefore, an initial viability analysis of Miu treated SKOV3 cells was performed. The 
treatment with Miu led to a significant reduction of viability at concentrations of 25 nM 
or higher (Figure 3.9 A). Hence, the concentration of 20 nM, which showed no induction 
of apoptosis (Figure 3.9 B), was chosen for analyzing low dose effects of Miu on cancer 
cells. Notably, short term treatment with Miu displayed slight alterations of actin 
cytoskeleton after 2 h and 6 h. At this time points Miu led to actin agglomerates in the 
cytoplasm. In contrast, over longer periods of treatment from 24 h to 72 h the structure 
of actin cytoskeleton seems to be recovered, except after 56 h treatment (Figure 3.9 C). 
Here, the Miu treated cells showed slightly altered actin around the nucleus. 
Nevertheless, the actin cytoskeleton seems to be recovered over treatment for 72 h with 
Miu. 
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Figure 3.9: Low dose treatment of SKOV3 with miuraenamide A (Miu) showed slight effects on 
cell functions. A: Cell viability after treatment for 72 h of SKOV3 cells with the indicated 
concentrations of Miu, n=3. B: Cell death analysis after treatment for 72 h with 20 nM Miu, n=3. 
C: Immunostaining of SKOV3 cells treated with 20 nM Miu for the indicated time points. Stained 
for actin (rhodamine-phalloidin, red), and nucleus (Hoechst 33342, blue), n=3. White bars indicate 
10 µm. ns, not significant. One-Way ANOVA/Bonferroni’s Multiple Comparison Test, *p < 0.05. 
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 Flow cytometry analysis indicated cell cycle alterations 3.2.2
Actin binding compounds are known to induce G2/M phase arrest,61 because of inhibition 
of cytokinesis, where the dynamic actin cytoskeleton is important.62 Therefore, the cell 
cycle and cell size were analyzed. The FACS analysis showed a Miu induced G2/M phase 
arrest after 72 h treatment in low dose treated SKOV3 cells, whereas, the size of cells 
remained unchanged. However, the inhibition of cell cycle seemed to be independent of 
alterations of the actin cytoskeleton and the results indicated alterations in cell 
homeostasis, even in low treatment concentrations with Miu. 
 
 Miu treatment specifically inhibited migration through pores 3.2.3
Previously, migration inhibitory effects could be achieved by treatment of cancer cells 
with the Miu related compound chondramide. Particularly, chondramide inhibited the 
migration of breast cancer cells, without inducing cell death.34 Unlike the preceding 
experiments with chondramide, the following migration tests were performed after 72 h 
pre-stimulation with Miu, recovery of the actin cytoskeleton (72 h, Figure 3.9 C), and the 
absence of compound during assays (Figure 3.11). These treatment terms should exclude 
obvious actin disrupting effects of Miu and could elucidate an additional role of Miu 
treatment on cancer cells. First, the Boyden chamber migration assay was performed, 
where the cells have to push through restricted pores by deforming their cell shape and 
sensing the applied nutrition gradient (Figure 3.11 A). The pre-treatment with Miu 
indicated a reduction of migration to 0.58-fold of control cells (Ctrl). Moreover, migration 
 
Figure 3.10: Cell cycle and cell size analysis of SKOV3 treated with miuraenamide A (Miu). 
SKOV3 cells were treated for 72 h with 20 nM Miu. A: Nicoletti cell cycle analysis, n=3. B: Flow 
cytometry analysis of cell size, n=3. Paired two tailed t-test, *p < 0.05. 
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associated processes were analyzed. The first steps in the migration of cancer cells are 
the adhesion and spreading of cells on a surface.63 These properties showed to be 
unaffected by Miu treatment (Figure 3.11 B). Further, the exact mechanism and reason 
for inhibited cell migration through pores were elucidated. To this end, the wound 
healing assay was performed. The Miu treated SKOV3 cells showed similar wound closure, 
comparable with untreated cells, whereas the negative control cells (neg Ctrl), which 
were cultivated in FCS free medium, indicated almost no migration (Figure 3.11 C). 
Furthermore, the secretion property of Miu treated HeLa_ssHRP cells was investigated. 
Those cells are stable transfected with a horse radish peroxidase (HRP) construct, which is 
tagged to a signal sequence (ss) for secretion.64 The secretion of migration stimulating 
factors is known to be important for the sufficient migration.65 Therefore, the stable 
transfected HeLa cells were used for analyzing cell transport machinery via the 
quantification of extracellular secreted HRP. The positive control treatment with 
brefeldin A impaired the HRP secretion during four hours, by preventing vesicle transport 
from the endoplasmic reticulum to the Golgi complex. Conversely, this was not the case 
for the Miu 20 nM pre-treatment or the repeated Miu stimulation over four hour 
secretion (Figure 3.11 D). To elucidate the effect of Miu treatment on the sensing of 
nutrition, the chemotaxis migration assay was conducted (Figure 3.11 E). The forward 
migration index (FMI) of SKOV3 cells and the velocity were not influenced by Miu and 
showed no significant inhibition after Miu treatment. From this data, we could conclude 
an inhibitory effect on SKOV3 cell migration after Miu pre-treatment, which could be 
shown in restricted migration and seemed to be deformation dependent. The 
examination of other migration assays like the wound healing, HRP secretion, and 
chemotaxis assay, demonstrated unaltered migration behaviors after Miu treatment. 
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Figure 3.11: Analysis of migration and associated parameters. SKOV3 cells were pre-treated with 
20 nM Miu over 72 h, during migration analysis no compound was present. A: Boyden chamber 
migration assay over 24 h migration through 8 µm pore membrane, n=4. B: Migration associated 
parameters, adhesion and spreading, quantified by counting adhered or spread cells, n=3-4. 
C: Wound healing assay, neg Ctrl: negative control, migration in FCS free medium. One 
representative image per treatment is shown, n=4. D: HRP secretion assay with HeLa_ssHRP, 
brefeldin A (BrefA) was used as positive control, fresh Miu was added (+4 h) or not (-4 h) during 
secretion, n=4. One-Way ANOVA/Bonferroni’s Multiple Comparison Test, *p < 0.05. E: Chemotaxis 
migration assay over 24 h migration along an FCS gradient. FMI, forward migration index, +/+ Ctrl: 
positive control, medium with FCS without FCS gradient, n=3. Paired two tailed t-test, *p < 0.05. 
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 Stiffness of the cell nucleus was altered by Miu treatment 3.2.4
The degree of cancer cell rigidity has previously been shown to be lower in comparison to 
non-cancer cells.66 Furthermore, the nucleus is the largest organelle in the cell and is 
supposed to be the limiting factor during migration through restricted pores.53,67 
Therefore, the mechanical properties of cells were elucidated by stiffness measurements. 
SKOV3 cells were treated with Miu for 72 h and the stiffness was measured with the 
atomic force microscope. The total cell stiffness was recorded by a defined force map of 
80x80 µm. The stiffness of nucleus could be determined by applying a specific force on 
the cell nucleus and both were calculated with the young’s moduli (see 2.9.3). The total 
cell stiffness of Miu treated SKOV3 cells was unaffected after treatment for 72 h (Figure 
3.12 A), whereas the stiffness of the nuclei showed alterations (Figure 3.12 B). The Miu 
treated cells displayed an enhancement of nuclear stiffness of 1.4-fold compared to 
control cells. These data indicated the influence of Miu low dose treatment on the 
mechanical properties of the cancer cell nuclei. 
  
 
Figure 3.12: Atomic force measurements of Miu treated SKOV3 cells. Cells were treated for 72 h 
with 20 nM miuraenamide (Miu) or DMSO as solvent control (Ctrl). A: Total cell stiffness was 
measured with a force map of 80x80 µm in contact mode, nine maps per experiment were 
measured, n=4, normalized young’s modulus/kPa B: Nuclear stiffness measurement with single 
force curves in contact mode, 10-20 cells per experiment were measured, n=4, normalized 
young’s modulus/kPa. Paired two tailed t-test, *p < 0.05. ns: not significant. The measurements 
were performed by Daniel Ruediger. 
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 Miu treatment had an impact on three dimensional migration 3.2.5
According to the stiffness measurements and Boyden chamber migration assays, life cell 
imaging was performed to visualize the three dimensional (3D) migration of SKOV3 cells 
after 72 h Miu stimulation. The migrating cells have to push through the confined 
network in the 3D environment and should be able to deform, while moving on their 
track. The pre-treated cells were seeded into rat tail collagen I gels with a concentration 
of 2 mg/ml and imaged over 20 h. The cellular phenotypes were separated into four 
groups: sprouting, squeezing, immobile, and dying (Figure 3.13). The sprouting type 
indicates cells, which create cellular protrusions, whereas the squeezing cells are ones, 
which manage the track limitation by pushing through restricted pores in the network. 
Further, immobile cells showed no protrusions and the dying cells depicted apoptotic 
bodies and cell fragmentation. The SKOV3 cells, which were treated with Miu, showed 
slightly fewer cells with sprouting and more immobile cellular phenotypes by trend. 
Moreover, Miu treatment indicated a lower amount of cells, which squeezed through 
restrictions on their migration track, whereas, cell death was just slightly increased in 3D 
migration of Miu treated SKOV3 cells. This data supports the Boyden chamber migration 
assay and the results of nuclear stiffness measurement. In conclusion, the 3D migration 
through a restricted network is inhibited by Miu treatment. 
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Figure 3.13: Rat tail collagen I 3D gel migration of SKOV3 cells. Cells were pre-treated for 72 h 
with 20 nM miuraenamide (Miu) and migrated over 20 h in collagen I gels (2 mg/ml). 
A: Quantification of cellular phenotypes normalized to total counted cell number (total no.), n=3. 
B: Example images of cellular phenotypes recorded by life cell imaging with transmitted light 
microscopy, n=3. C: Example images of cellular phenotypes depicted with fluorescence 
microscope, stained for actin (rhodamine-phalloidin, red), and nucleus (Hoechst 33342, blue), 
n=3. Black and white bars indicate 10 µm. Blue arrows depict the deformed nucleus due to 
restriction.  
 Proteome analysis indicated regulated proteins after treatment for 56 h 3.2.6
We were interested in the amount of proteins affected by Miu treatment to elucidate the 
responsible signaling mechanisms for changes of nuclear stiffness. Therefore, the 
proteome analysis of Miu treated SKOV3 cells was performed over a treatment period of 
96 h. The alterations of 7328 proteins were recorded after Miu treatment over time with 
the MaxQuant proteome analysis. The heat plot depicted clusters with up- or down-
regulated proteins at earlier time-points (red or green, Figure 3.14 A), which could be 
explained by counter regulatory mechanisms or the alteration of actin regulated 
transcription factors due to actin agglomerations after approximately 4 h stimulation.20 
Furthermore, two prominent clusters were found after treatment for 56 h, which were 
analyzed further (Figure 3.14 B). A few actin associated proteins were up-regulated at this 
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time point (B, red graph), whereas the enrichment analysis of down-regulated proteins 
after treatment for 56 h showed different regulated pathways (Figure 3.14 C). The 
pathways with a false discovery rate (FDR)60 of < 0.2 (orange dots) and enrichment values 
of > 2 (red dots) were determined as important altered pathways (Wnt-signaling pathway, 
autophagy, Epithelial cell signaling in H. pylori infections), whereas KEGG Wnt-signaling 
pathway indicated 17 proteins with an enrichment of 3.33 and FDR of 1.37x 10-3. The 17 
proteins of Wnt-signaling pathway in the down-regulated 56 h treatment cluster are 
listed in Table 3.1 and depicted a highly connected network (Figure 3.14 D). This indicated 
the highest influence of Miu treatment on Wnt-signaling pathway. In conclusion, the 
proteome analysis showed alterations of the Wnt-signaling pathway after Miu treatment 
eight hours before 3D migration was inhibited (Figure 3.11). The marked Wnt-signaling 
proteins in Table 3.1 were supposed to be regulated by actin and indicated transcription 
regulating activity. For instance, the function of nuclear factors of activated T-cell (NFATs) 
was associated to actin cytoskeleton and actin regulates the nuclear duration of this 
transcription factor.68,69 Likewise, the histone acetyltransferase p300 turned out to be 
down-regulated in proteomics and implicated the link to actin cytoskeleton via the 
transcription co-activator MRTF-A.70 For these reasons, the Wnt-signaling and the 
mentioned actin associated proteins were further analyzed. 
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Figure 3.14: Proteome analysis with MaxQuant, Perseus data processing and StringDB analysis.
SKOV3 cells were treated with Miu 20 nM for indicated time points. A: Heat plot with ten defined 
row clusters, red areas indicate up- and green areas indicate down-regulation. B: Defined cluster 
up- and down-regulated proteins after 56 h treatment depicted in lanes as time series. C: Dot plot 
of enriched pathways with a threshold of FDR < 0.5 showed down-regulated proteins after 56 h 
treatment, orange dots: FDR < 0.2, red dots: FDR < 0.2 and enrichment value > 2. D: StringDB 
analysis of highest pathway enrichment (Wnt-signaling) in indicated cluster. Interaction sources 
were adjusted to experiments, databases, co-expression, neighborhood, gene fusion, and co-
occurrence. Minimum required interaction score was 0.4, whereas thicker and darker gray 
connections represent higher confidence of interaction score. Proteome analysis with MaxQuant
and Perseus data processing was conducted by Dr. Yu (Proteomics and Bioanalytics TU Munich). 
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Table 3.1: Genes of Wnt-signaling enrichment  
No Gene names Protein names
1 CHD8 Chromodomain-helicase-DNA-binding protein 8
2 CSNK1A1 Casein kinase I isoform alpha
3 CSNK1E Casein kinase I isoform epsilon
4 CSNK2A2 Casein kinase II subunit alpha
5 CTNNBIP1 Beta-catenin-interacting protein 1
6 DVL3 Segment polarity protein dishevelled homolog DVL-3
7 EP300 Histone acetyltransferase p300
8 MAPK9 Mitogen-activated protein kinase 9
9 NFAT5 Nuclear factor of activated T-cells 5
10 PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 
11 PPP2R1B Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform 
12 PPP2R5C Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma 
isoform 
13 PPP3R1 Calcineurin subunit B type 1
14 RAC2 Ras-related C3 botulinum toxin substrate 2
15 RAC3 Ras-related C3 botulinum toxin substrate 3
16 RHOA Transforming protein RhoA
17 RUVBL1 RuvB-like 1 
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 Miu treatment impaired Wnt-signaling transcription factors 3.2.7
The transcription factor β-catenin is one of the key activators of Wnt-signaling, and it is 
mobilized by uncoupling from inhibitors and translocation to the nucleus.71 The ability of 
β-catenin to bind to the TCF/Lef1 promoter and to activate the transcription could be 
tested by the luciferase reporter gene assay. The promoter plasmid pFOPFlash (mutant 
pTOPFlash) was transfected to exclude the unspecific effects of Miu treatment on 
transcription. Notably, the activation of promoter and transcription of luciferase was not 
affected by Miu treatment (Figure 3.15). Nevertheless, it should be noticed that TCF/Lef1 
could also be activated independent from β-catenin.72 
 
Subsequently, the translocation and hence the activation of β-catenin and NFAT5 to the 
nucleus was analyzed. First, β-catenin localization after stimulation with LiCl and 
simultaneous treatment with Miu was examined. The quantification showed a 
translocation of β-catenin to the nucleus after LiCl stimulation, which indicated a trend to 
inhibition after Miu treatment for 56 h (Figure 3.16 A). Additionally, the non-canonical, 
β-catenin independent transcription factor NFAT573 was stained for nuclear localization 
after Miu treatment (Figure 3.16 B). The translocation of NFAT5 was also inhibited by 
trend after Miu treatment and indicated a more general inhibition of transcription factor 
translocation by Miu treatment. 
 
 
Figure 3.15: β-catenin promoter TCF/Lef1 reporter gene assay. Cells were treated for 56 h with 
20 nM miuraenamide (Miu) and/or LiCl 40 mM. The signal of renilla luciferase activity was 
normalized to firefly (constitutive active promoter) and pFOPFlash (TOPFlash mutant), n=3. 
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Figure 3.16: Confirmation of Wnt-signaling pathway alteration. SKOV3 cells treated with 20 nM 
Miu for 56 h. A: Immunostaining of β-catenin after Miu and/or LiCl 40 mM stimulation, and the 
quantification of nuclear localization (bar diagram), β-catenin (antibody, green), n=3. 
B: Immunostaining of NFAT5 after Miu stimulation, and the quantification of nuclear localization 
(bar diagram), NFAT5 (antibody, green), n=3. One representative image per treatment is shown. 
Staining of actin (rhodamine-phalloidin, red) and nucleus (Hoechst 33342, blue). White bars 
indicate 20 µm. 
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 Miu treatment reduced the protein level of p300 3.2.8
The histone acetyltransferase p300 (also EP300) is a transcription co-activator, which is 
crucial for the expression of many proteins and is overexpressed in different cancers.74 It 
is important in Wnt-signaling and builds multi-protein complexes with transcription 
factors like β-catenin75 or MRTF.70 Figure 3.17 A depicts the immunostaining of the 
transcription co-activator p300 and indicated that the nuclear localization of p300 was 
not impaired by Miu treatment. Furthermore, the protein level of p300 was analyzed 
after stimulation for 56 h with Miu. The treatment showed a down-regulation of protein 
levels to 0.6-fold compared to control (Figure 3.17 A). The mRNA level was also affected 
by Miu treatment (0.8-fold), which indicated a reduction of p300 expression. This 
reduction of protein level seemed to be reduced at least in part by impaired p300 mRNA 
transcription (Figure 3.17 B). These data emphasized the influence of Miu treatment on 
the p300 transcription co-activator expression and confirmed the evidence of proteome 
examination after Miu treatment for 56 h. 
 
Figure 3.17: Localization and expression analysis of p300 on protein and mRNA level. SKOV3 
cells were treated with 20 nM Miu for 56 h. A: Immunostaining of p300 (antibody, green), actin 
(rhodamine-phalloidin, red) and nucleus (Hoechst 33342, blue), n=2. White bars indicate 20 µm.  
B: Protein level of p300 with the quantification. One representative image per treatment is 
shown, n=4. C: RQ-values of p300 mRNA level, n=2. Paired two tailed t-test, *p < 0.05. 
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 MRTF-related genes were down-regulated by Miu treatment 3.2.9
The proteome data was analyzed concerning MRTF-regulated or associated genes. The 
selection of genes was collected by GeneCards®76 Keyword Search “MRTF” (Table 3.2). 
Notably, most of the listed genes are down-regulated by Miu treatment (Figure 3.18). A 
few of them strongly related to migration regulating processes. For instance, LIMA1 
expression (also called Eplin) is regulated by MRTF,77 and showed lower protein levels 
after Miu treatment in proteome analysis. Proteins, which are known for their interaction 
with MRTF and simultaneously regulate migration processes, like SMYD378 and MICAL79, 
were expressed in lower levels in comparison to control. Likewise, importins, which 
regulate nuclear MRTF transport (KPNA3, KPNB1)80, were down-regulated after Miu 
treatment. Hence, the data strongly indicated the alteration of MRTF-related genes in a 
migration regulating context after Miu low dose treatment. 
 
Figure 3.18: Proteome analysis of MRTF-associated genes. SKOV3 cells were treated with 20 nM 
miuraenamide for 56 h (Miu, black bars) or harvested at stimulation start point without treatment 
(Ctrl, white bars). 
 
Table 3.2: Proteome analysis of MRTF-associated genes 
No Gene name Protein description 
1 ATE1 Arginyl-tRNA-protein transferase 1 
2 BRMS1L Breast cancer metastasis-suppressor 1-like protein 
3 C1QTNF6 Complement C1q tumor necrosis factor-related protein 6 
-3,0
-2,5
-2,0
-1,5
-1,0
-0,5
0,0
0,5
1,0
1,5
2,0
2,5 E
P3
00
SM
YD
3
RH
OA
M
IC
AL
2
AT
E1
KP
NA
3
M
KL
1
BR
M
S1
L
DN
M
T1
M
KL
2
LIM
A1
KP
NB
1
C1
QT
NF
6
ST
AT
3
TR
IM
27
CY
R6
1
SR
F
PA
LL
D
Ctrl Miu
down up
 
 
RESULTS 
 
55
 
No Gene name Protein description 
4 CYR61 Protein CYR61 
5 DNMT1 DNA (cytosine-5)-methyltransferase 1 
6 EP300 Histone acetyltransferase p300 
7 KPNA3 Importin subunit alpha-4 
8 KPNB1 Importin subunit beta-1 
9 LIMA1 LIM domain and actin-binding protein 1, also Eplin 
10 MICAL2 Protein-methionine sulfoxide oxidase MICAL2 
11 MKL1 MKL/myocardin-like protein 1 
12 MKL2 MKL/myocardin-like protein 2; Phosphatase and actin regulator 
13 PALLD Palladin 
14 RHOA Transforming protein RhoA 
15 SMYD3 Histone-lysine N-methyltransferase SMYD3 
15 SRF Serum response factor 
17 STAT3 Signal transducer and activator of transcription 3; Signal transducer 
and activator of transcription 
18 TRIM27 Zinc finger protein RFP 
 
The transcriptional co-activator p300 interacts with the transcription factor MRTF-A and 
the interaction proved to activate migration regulatory genes.70 Therefore, the gene 
expression of CYR61, which is a migration-related gene regulated by MRTF-A, was 
examined (Figure 3.19). The treatment of SKOV3 cells over 72 h with Miu showed a 
significantly reduced expression level of CYR61 (0.8-fold). After treatment for 56 h, no 
alteration of the CYR61 mRNA level was detectable, indicating a time-dependent 
regulation of CYR61, which is down-stream of p300 expression reduction. 
 
Figure 3.19: Expression analysis of CYR61 mRNA level. SKOV3 cells were treated with 20 nM Miu 
for 56 h or 72 h. RQ-values of CYR61 mRNA level, n=3. Paired two tailed t-test, *p < 0.05. 
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4 DISCUSSION 
4.1 Cytoskeletal binding compounds in clinical use 
Natural compounds, which influence the cellular cytoskeleton, have been used very 
successfully for decades in cancer treatment. Microtubule manipulating substances such 
as paclitaxel, epothilone or colchicine, are not only established in the clinic for cancer 
treatment, but also amongst others, for the treatment of inflammatory disease.31,81 
However, a pharmacological therapy of patients suffering from cancer with actin binding 
compounds is still missing, although numerous studies have pointed out the effectiveness 
against tumor cells in vitro and in vivo.33,34,37 The incidence of side effects and resistant 
mechanisms are still the limiting factors for the approval of actin binding compounds and 
chemotherapeutic drugs in general. Known resistance mechanisms are, e.g., the induction 
of efflux pump expression in line with the multidrug resistance (MDR) gene activation, 
mutations of target enzymes, enhanced drug degradation, or increased DNA damage 
repair.82 Limitations are also given by life-threatening side effects as cardiotoxicity, 
nephrotoxicity or neurotoxicity.49 
Modern clinical approaches concentrate on circumventing those resistance mechanisms 
and attempt to decrease side effects. For instance, side effects could be reduced by 
chemotherapy consisting of the combination of treatments with two or more 
compounds. But most of the applied combinations are empirically designed and 
concentrate on pharmacokinetic profiles or biological interactions between drugs.83 Thus, 
the understanding of mechanisms, which lead to synergistic effects of distinct drug 
combinations, could further improve cancer therapy. Novel chemotherapeutic drugs 
might target counter regulatory mechanisms of one combination partner and therefore 
achieve greater therapeutic success. Herein, we represented two novel approaches in 
order to decrease limiting side effects of cancer therapy and to elucidate underlying 
mechanisms. 
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4.2 Combination treatment with doxorubicin and chondramide B 
This study pointed out that the successful combination of actin binding compound ChB 
and DNA damage induction emerged from increased DNA damage due to altered DNA 
damage response (DDR). We elucidated the synergistic mechanism and demonstrated the 
implication of the Golgi complex in this process.  
Mechanisms of DNA damage response are known to be linked to organelle function in the 
cell. For instance, the tumor suppressor protein p53 links DDR to mitochondria in order to 
induce mitochondrial release of cytochrome C, leading to the induction of intrinsic 
apoptosis.84 Whereas the mitochondria and the nucleus represent well-known organelles 
in DDR, the role of the Golgi complex is poorly understood. Only recently, the Golgi 
complex has been described to be crucial in DDR.43 
The first part of this study followed a novel approach, where the Golgi dependent DDR 
could be prevented. In particular, the Golgi complex localization was altered by inhibiting 
actin dynamics after chondramide (ChB) treatment. Farber-Katz described a DDR signaling 
cascade, based on the Golgi phosphoprotein 3 (GOLPH3), which most probably regulates 
the transport processes between the nucleus and the plasma membrane. They postulated 
the activation of the GOLPH3 dependent signaling cascade after DNA damage induction. 
The DNA dependent protein kinase (DNA-PK) is activated and led to a force transmission 
from GOLPH3 to myosin 18A (Myo18A) by means of the actin cytoskeleton. The group 
indicated the importance of the Golgi complex dependent signaling cascade for the 
survival of cancer cells.43 In addition, we could show that cancer cells reacted sensitive to 
the inhibition of Golgi dispersal by chondramide treatment, which led to a 
hyperpolymerization of actin. Comparable effects were observed by DNA damage 
induction and simultaneous inhibition of DNA-PK, which triggers the DDR and activates 
the signaling cascade, ending in disrupted Golgi dynamics. 
 Inhibition of GOLPH3 pathway is a potential target in cancer therapy 4.2.1
According to the outlined implication of Golgi dispersal in DDR, proteins of the GOLPH3 
signaling cascade can serve as a target for cancer therapy. Notably, the Golgi complex-
associated GOLPH3 is overexpressed in many cancer types and is known to correlate with 
a poor prognosis in several cancerous diseases.85-87 It is located at the trans-Golgi 
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membrane via a phosphatidylinositol-4-phosphate (PI4P) link and is known to be 
important for Golgi trafficking.88,89 The primary function of the Golgi complex is the 
processing of glycosylated proteins and is therefore important for the activation of 
various proteins and receptors.90,91  
In particular, members of the toll like receptor (TLR) family are activated by glycosylation, 
which further leads to a proper localization and function of the receptors.92 Interestingly, 
the TLR activation was described to increase DNA damage repair.93 Moreover, DNA repair 
enzymes, like ATM94 and DNA-PK95, are supposed to be activated or persist longer in an 
activated state due to glycosylation. The relation of GOLPH3 pathway inhibition, followed 
by a reduction of the nucleus to plasma membrane transport, might links the Golgi 
dispersal to DNA damage repair mechanisms.  
Secretion processes do not exclusively rely on GOLPH3, but also on its interaction partner 
Myo18A.89 The unconventional Myo18A contains an actin binding domain, by which it 
interacts with actin filaments and transmits the signal for Golgi dispersal to the actin 
cytoskeleton. Consequently, Myo18A links the actin cytoskeleton to the DDR. We could 
show that treatment with ChB results in entrapment of Myo18A in actin agglomerates 
and therefore leads to an impairment of its localization. Likewise, previous studies with 
ChB demonstrated the trapping of other oncoproteins in actin agglomerates followed by 
specific cancer cell death induction.33  
Our group demonstrated the feasibility of actin binding drugs, like ChB, for the use in 
cancer therapy, by targeting known cancer signaling pathways. We provided a new 
combination approach for inhibiting GOLPH3 signaling transduction via the trapping of 
Myo18A, which further leads to the disruption of Golgi complex dependent DDR. 
Although, targeting GOLPH3 in cancer cells seems to be an appropriate approach for 
fighting cancer, to our knowledge, no inhibitor exists. With the combination of Doxo, DNA 
damage induction and inhibition of Golgi complex dependent DDR via ChB treatment, we 
provide a novel combination therapy based on the knowledge of counter regulatory 
mechanisms. 
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 Cell line specific effects confirm the importance of Golgi dispersal 4.2.2
The implication of the Golgi complex in DDR has been poorly studied, but represents a 
promising target in cancer therapy. In order to gain further insight, we examined different 
cell types to define the specificity of treatment in various cell lines. Notably, the 
combination treatment of Doxo and ChB elucidated a cell line specific cell death response, 
which could be attributed to an altered Golgi complex dependent DDR. SKBR3 cells, in 
contrast to MDA-MB-231 and T24 cells, displayed no Golgi dispersal after DNA damage 
induction with Doxo. After the simultaneous treatment with Doxo and ChB the 
localization of the SKBR3 Golgi complex remains stable in comparison to the responding 
cell lines. Accordingly, the combination treatment did not have an impact on cell death 
induction of SKBR3 cells. The specific response of cell lines after DNA damage on the 
function of organelles was described before. Whaba et al. tested the translatome in three 
glioblastoma cancer cell lines after ionizing radiation and showed cell-line specific 
changes in mitochondria.96 Obviously, the response of cell organelles seemed to vary 
among cancer cell lines. The importance of the Golgi dispersal for DNA damage repair was 
emphasized, by the results of SKBR3 cells, which showed no induction of DNA damage 
and cell death after combination treatment. The success of combination treatment has 
previously turned out to be limited. For instance, the combination of tamoxifen, which 
targets estrogen receptor (ER)-positive breast cancer, with classic cytostatic drugs showed 
positive results in clinical trials, but may have no impact on ER-negative breast cancer 
tissue.97 Thus, the impact of precision medicine increases continuously and pre-clinical 
tests like microarray analysis of tumor markers have been implicated in cancer therapy.98 
On the one hand the cell line specificity of Doxo and ChB combination treatment reflects 
the limitations of combination treatment, but on the other hand it could establish the 
Golgi dispersal as a novel predictor of therapy effectiveness in cancer treatment.  
 Benefits and risks of targeting the actin cytoskeleton 4.2.3
Equally important to the knowledge of cancer signaling targets are the presence or 
absence of side effects. Prior to the application in the clinic, drugs have to be proved on 
efficacy and safety. The occurrence of side effects represents one important limiting 
factor in clinical trials. Thus, secondary effects in patients could be diminished by reducing 
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the treatment dose and by applying more than one compound. The combination therapy 
should exclude negative interactions or additive side effects, like cardiotoxicity. For 
instance, Doxo inhibits cancer cell growth and induces DNA damage by diverse modes of 
actions, but induces prominent side effects in patients. Besides the inhibition of 
topoisomerase II, Doxo affects the mitochondrial electron transport chain, which was 
supposed to be responsible for the considerable cardiotoxicity of Doxo therapy.49 
Interestingly, the treatment with actin hyperpolymerizing compound jasplakinolide also 
showed toxic effects on cardiomyocytes due to inhibition of cardiac ion channel activity.99 
Furthermore, the treatment with actin disrupting agent cytochalasin D displayed 
dysfunctional volume regulations of neonatal rat cardiomyocytes.100 We observed the 
effect of the combination treatment of ChB and Doxo on cardiomyocytes and endothelial 
cells. In contrast to the results with the previously stated actin binding compounds, this 
study demonstrates the actin binding compound ChB as an appropriate combination 
partner for Doxo. The single treatment with ChB did not have an impact on 
cardiomyocytes. Additionally, in combination with Doxo, ChB did not show an undesirable 
effect on cardiomyocytes number and area. Thus, the combination of ChB and Doxo 
displayed a substantial lower effect on cardiomyocyte compared with Doxo single 
standard dose treatment of 1000 nM.101 
We also investigated the effects on human umbilical vein endothelial cells (HUVECs) as a 
model for physiological blood vessel endothelium.102 Higher treatment concentrations of 
Doxo are known to induce DNA damage and cell death in HUVECs.103 Notably, we 
showed, that the apoptosis rate of HUVECs was unaffected by lower Doxo concentration 
in single or combination treatment. Accordingly, the observed body weight of mice 
indicated a good tolerance of combined therapy in vivo. These findings reinforce the 
potential of actin binding compounds for Doxo treatment combinations to reduce limiting 
side effects. 
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4.3 Low dose miuraenamide beyond actin hyperpolymerization 
Various studies discussed the migration inhibitory effect of actin binding compounds and 
demonstrated the importance of the actin cytoskeleton for the mobility of tumor 
cells.34,104 However, those effects could be explained by primary effects on the actin 
structure. Miuraenamide, similar to ChB, stabilizes the filament form of actin and has 
inhibiting effects in cancer growth with concentrations of IC50 values from 3.7 nM to 
79.6 nM.37 Also in migration inhibitory experiments, prominent actin alterations were 
visible in rhodamine-phalloidin staining, where the actin structure is disrupted to actin 
agglomerates. Those effects were prominently detected after treatment with high 
concentrations of the actin binding compound. The cancer cells were usually treated for a 
short period of time and compounds were present during the migration assays. Previous 
results of our group indicated inhibitory effects of ChB treatment on migrating cancer 
cells due to an alteration of stress fiber formation and inhibition of RhoA signaling. The 
strong effect on the actin cytoskeleton after 8 h treatment was improved after the 
removal of ChB. Recently research investigated the same recovery of actin cytoskeleton 
after compound removal. Lazaro-Dieguez et al. provided evidence for the participation of 
autophagosomal degradation of the actin agglomerates.105 On the contrary, the cancer 
cells in this study were incubated over a few days with low doses of Miu without 
removing the compound. With the lower dose treatment, the cytoskeletal actin structure 
recovers in the presence of Miu. Hence, we showed migration inhibitory effects of Miu 
beyond the disruption of the actin cytoskeleton. 
 Effects of Miu low dose treatment on the migration through pores 4.3.1
We could show specific inhibitory effects of Miu after visible recovery of the actin 
cytoskeleton. The treatment with a concentration of 20 nM showed no effect on viability 
and cell death induction after 72 h, which represents the starting point of investigations. 
Furthermore, the first hint of an altered cellular state after long term treatment with Miu 
was a slight increase of G2/M phase arrest. The alteration of cell cycle due to actin binding 
compounds was described previously, but as stated earlier, in these cells the effect could 
be attributed to huge alterations of the actin cytoskeleton due to the higher treatment 
concentrations.61  
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The key experiment represented the impaired migration of ovarian cancer cell line SKOV3 
during Boyden chamber migration assay. Notably, we showed the inhibition of migration 
after 72 h treatment with low dose Miu concentration, which was not dependent on 
alteration of adhesion or spreading processes of cancer cells. To clarify the exact 
mechanism, further migration assays were conducted. Interestingly, the mobility of 
SKOV3 cells was not inhibited in wound healing assay. In addition, we wanted to elucidate 
the consequences of Miu treatment on the sensing of a nutrition gradient. Therefore, we 
analyzed the effects in chemotaxis migration assay. The cells follow an FCS gradient 
without restriction on their path. The forward migration index (FMI) and the velocity of 
SKOV3 cells were not reduced by Miu pre-treatment. These data, together with the 
finding of unimpaired secretion, detected by HRP secretion assay, indicate no influence of 
treatment on the sensing of a nutrition gradient. The migration of cancer cells is 
dependent on transport and secretion processes from the nucleus to the plasma 
membrane.65,106 As an example, integrin and growth factor receptors were transported to 
the migration site for sensing nutrition and stabilizing the migration process by binding to 
the surface.107,108 The intact secretion after Miu treatment further affirm the intactness of 
actin cytoskeleton, because actin is important in vesicle transport from nucleus to 
cytoplasm in the secreting cell.108,109 In summary, the migration inhibition of Miu treated 
cancer cells was independent of cytoplasmic actin and indicated specific inhibition of 
motility exclusively in three dimensional (3D) movements. 
 Miu treatment modified the nuclear stiffness of cancer cells 4.3.2
Modern research focuses on the physical properties of migrating, dying or differentiating 
cells. The stiffness of cells and isolated organelles, such as the nucleus, has been linked to 
basic cellular processes.67,110 Existing studies elucidated the alteration of cellular stiffness 
according to the differentiation state of cells.111 In addition, cancer cells have softer 
cellular structures in comparison to non-cancer cells. The migration of cancer cells in a 3D 
environment is dependent on the cell rigidity and extra cellular matrix mechanics.66 Not 
only cellular, but also stiffness of the nucleus can be a critical determinant of the 
successful migration of cancer cells.53 Our results showed increased nuclear stiffness in 
cancer cells upon Miu treatment. 
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There are several factors, which have been described to have an impact on the stiffness 
of nuclei. Firstly, cytoskeletal tension influences the nuclear deformation by cytoplasmic 
actin dynamics and actin binding proteins.112 Secondly, lamins anchor the chromatin to 
the cytoplasmic actin, which is associated to the nuclear envelope, and therefore, might 
stabilize the rigidity of the nuclear membrane.113 Thirdly, the DNA condensation status 
and chromatin structure, which is regulated by histone acetylation and deacetylation, 
have an impact on the nuclear stiffness. For instance, treatment with histone deacetylase 
(HDAC) inhibitors, such as trichostatin A, led to the decondensation of chromatin and 
indicated softer nuclei.67,110 Moreover, the inhibition of cytoplasmic myosin II with 
blebbistatin showed to induce stiffer nuclei in cardiac myocytes.110 
One hypothesis for the inhibition of migration by Miu low dose treatment is the reduction 
of nuclear deformability.112 Therefore, the specific effect of migration inhibition in Boyden 
chamber assay might be dependent on nuclear stiffness. Miu treated cells showed almost 
normal two dimensional (2D) migration characteristic, which was measured by 
chemotaxis and wound healing assay, but lost the ability of 3D migration through 
restricted pores. To confirm this hypothesis, cell migration properties were analyzed using 
3D collagen I gels. Indeed, Miu treated cancer cells showed a lower number of 
deformable cells, reduced mobility, and decreased the amount of cells, which successfully 
squeezed through restricted pores. Accordingly, a recently published study postulated the 
need of a contractile perinuclear actin system for sufficient migration in a confined 
environment. Furthermore, the perinuclear actin protects the cells during 3D migration 
from apoptosis, but is probably neglectable in 2D migration.114 In conclusion, the results 
pointed to an effect on 3D migration accompanied by an enhanced nuclear stiffness, 
which might be attributed to effects of Miu on perinuclear actin. 
 Proteome indicated an alteration of transcription factor signaling 4.3.3
Cytoplasmic actin disruption has been postulated to have an impact on alteration of 
protein signaling.20 We performed time-course proteome analysis in order to obtain 
insights into affected proteins in a time-dependent manner. 
In accordance with the actin staining, large alterations of proteins were recorded after 
early time points of Miu treatment. Those effects on protein expression due to 
 
 
DISCUSSION 
 
64
 
cytoplasmic actin disruption were described before.20 Of note, the proteome data 
displayed the down-regulation of a prominent protein cluster a few hours before the 
effect on migration was observed. This might indicate a functional correlation of 
migration inhibition and the alterations of protein levels.  
Notably, the pathway of lowest FDR and simultaneously an enrichment factor over two 
was the migration-associated Wnt-signaling pathway. Transcription factors or co-factors 
such as NFAT5 and p300, which are linked to the Wnt-signaling pathway, were 
significantly down-regulated in proteome analysis. Accordingly, we could demonstrate 
the inhibition of nuclear translocation of Wnt-signaling transcription factors β-catenin and 
NFAT5. In addition, the reduction of p300 protein level could be confirmed in further 
experiments. Conversely, the observation of Wnt-reporter gene assay with TCF/Lef1 
promoter region indicated no transcriptional alteration after Miu treatment. One 
explanation could be the β-catenin independent activation of TCF/Lef1 promoter, which 
was previously described in hematopoietic cancer cells.72 Independent TCF/Lef1 promoter 
activation was postulated before in SKOV3 cells.115 In contrast to the alteration of 
β-catenin and NFAT5 translocation, the localization of p300 was not influenced, but the 
protein level of the transcription co-activator p300 was significantly diminished.  
To our knowledge, no direct connection of Wnt-signaling and induction of nuclear 
stiffness exists. Wnt-pathway is, however, important in epithelial mesenchymal transition 
(EMT). The transformation of epithelial cells to mesenchymal phenotype enables them to 
migrate and disseminate to distant organs. The Wnt-signaling pathway was supposed to 
induce EMT in tumor cells.116 Besides the activation of Wnt-signaling, the changes of 
morphology characteristics are one hallmark of EMT.117 Cancer cells, which underwent 
EMT, have a softer cellular structure and higher migration potential. Consequently, this 
indicates a lower migration potential of cancer cells with increased cellular stiffness after 
inhibition of EMT.118 There is an evidence for the alteration of EMT due to Miu treatment 
by disrupting Wnt-signaling-associated transcription factors, followed by increased 
nuclear stiffness. 
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 Down-regulation of p300 linked nuclear stiffness to transcriptional 4.3.4
alteration 
With reference to the promising results of p300 down-regulation in proteome analysis 
and Western blot, the regulation and interaction partners of p300 were examined. 
Together with its functionally related partner CREB binding protein (CBP), p300 possesses 
acetyltransferase and transcription co-activator characteristics and is assumed to have 
many functions in the regulation of transcription and chromatin remodeling.74 The 
enhancement of histone acetylation was previously postulated to be prominent in cancer 
cells, which have a high transcriptional activity, accompanied by decondensation of 
chromatin.119 Accordingly, the condensation and decondensation of chromatin structure 
have an impact on the nuclear stiffness. We demonstrated the reduction of p300 protein 
level after Miu treatment, which might have led to a down-regulation of acetylation of 
histones and therefore to the condensation of chromatin. Although, the acetylation state 
of Miu treated cells, have to be tested in further investigations, the functional relation of 
p300 and stiffness induction is probable. One possibility is that the decrease of histone 
acetylation might elevate the nuclear stiffness. The contrary was postulated for the 
inhibition of deacetylation, which reduced the nuclear stiffness.94,95 
Besides the alteration of histone acetylation, p300 was found to interact with the 
transcription co-factor MRTF. Both transcriptional co-activators synergistically promoted 
cell migration and the transcription of migration-related genes.70 Indeed, we could 
confirm this study by the investigation of MRTF-associated proteins in proteome analysis. 
Notably, 14 out of 18 observed MRTF-associated proteins were down-regulated after Miu 
treatment, indicating a strong connection of p300 to MRTF. These data could be 
reinforced by the achieved down-regulation of the migration-associated gene CYR61. 
Furthermore, CYR61 was found to be activated by mechanical stress due to MRTF/CBP in 
smooth muscle cells.120 The activation of p300-MRTF-related genes might be dependent 
on mechanical stress during restricted 3D migration. Miu might reduce the translocation 
of specific transcription factors, followed by down-regulation of p300 and a fewer 
acetylation of histones. This may finally increase the chromatin condensation, 
accompanied by the enhancement of nuclear stiffness, subsequently leading to an 
inhibition of migration. In conclusion, we presented an impact of mechanical alteration 
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after Miu treatment on protein and transcriptional level. However, more examinations on 
the connection of p300, nuclear stiffness and transcription factor localization are needed 
to conclude the exact mechanism of Miu long term treatment and inhibition of 3D cell 
migration.  
4.4 Future perspectives 
The combination of ChB with DNA damaging agent Doxo represents just the beginning of 
promising applications of actin binding compounds in cancer therapy. It will open an 
attractive field of research to find appropriate combination partners for actin binding 
compounds. Since actin is an ubiquitously expressed protein, it interacts with a lot of 
cellular compartments and signaling cascades. We could show the specific inhibition of 
cancer cell growth by targeting counter regulatory mechanisms, but more investigations 
should be performed on the function of actin and its interacting proteins. 
Furthermore, optimization of chemical structure of ChB, concerning chemical synthesis 
and specificity could be examined. Herein, we provide Miu as an alternative to the 
complex synthesis of ChB. Particularly, the chemical structure of Miu is more accessible to 
chemical synthesis and could be easily modified. Current studies concentrate on the 
modification of Miu to obtain derivatives, which demonstrate the functionality on cancer 
cells beside prominent actin disrupting effects. Moreover, this study highly supports the 
assumption, that myxobacterial derived compounds such as Miu, have an impact on 
cellular functions beside the alteration of actin dynamics in the cytoplasm. In line with 
these examinations, further research should observe the evidence of physical properties 
on transcription regulation and the nuclear actin structures altered by actin binding 
compounds. Therefore ChB and Miu represent tools for further investigations of actin as a 
potential target. 
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5 SUMMARY 
The cytoskeleton of cancer cells has been proved to be an attractive target for tumor 
therapy in patients. In contrast to the inhibition of microtubule structure with 
chemotherapeutic drugs like paclitaxel, the actin binding compounds have not achieved 
the use in clinics yet. One limiting factor for the application of actin binding compounds in 
patients might be the expected side effects of higher treatment concentrations. Hence, 
the pharmacological targeting of the actin cytoskeleton in lower treatment 
concentrations as well as in combination with common chemotherapeutics may 
represent new approaches for the use of actin binding compounds in cancer therapy. 
Furthermore, there is an urgent need to understand the molecular mechanism of the 
tested compounds to design rational therapy strategies. 
This study introduces the actin binding compounds chondramide and miuraenamide as 
tools for the inhibition of cancer cell survival and migration. Firstly, we show the high 
potential of actin binding compounds to inhibit the DNA damage response after 
combination treatment with the topoisomerase inhibitor doxorubicin. The combination 
treatment of chondramide and doxorubicin displays a disruption of Golgi dependent DNA 
damage response and indicates the increase of DNA damage and cell death in cancer 
cells. Furthermore, the combination treatment has negligible effects on non-cancer cells 
and achieves a reduction of tumor volume in vivo. Secondly, we demonstrate the effect of 
low dose miuraenamide treatment on migration of cancer cells. The cell migration in a 
three dimensional environment is significantly reduced after miuraenamide treatment 
and is elucidated to be nuclear stiffness dependent. Furthermore, the proteome analysis 
indicates the inhibition of migration-related signaling in cancer cells, for instance, proteins 
of the Wnt-signaling pathway and MRTF/SRF-associated proteins are down-regulated 
after miuraenamide treatment.  
In summary, this work provides evidence for the implementation of actin binding 
compounds in cancer therapy and shows the specific effects of the compounds on two 
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hallmarks of cancer, beyond simple disruption of the actin cytoskeleton. This study 
outlines the pro-apoptotic and anti-metastatic potential of chondramide and 
miuraenamide in low dose treatment. In conclusion, we evaluated novel unconventional 
treatment approaches in cancer for the further application of actin binding compounds. 
 
Figure 5.1: The mechanisms of chondramide B and miuraenamide A treatment. A: Inhibition 
mechanism of DNA damage response (DDR) by means of Golgi dispersal. Doxorubicin induces DNA 
double strand breaks, which further leads to the activation of Golgi dependent DDR. Induced 
Golgi dispersal is inhibited by chondramide B, causing enhanced DNA damage and cell death in 
cancer cells. B: The increased nuclear stiffness and the alteration of transcription signaling after 
miuraenamide A treatment leads to migration inhibition. The treatment with miuraenamide A has 
an impact on transcription factors in Wnt-signaling pathway, and reduces migration-related gene 
expression, which is followed by the reduction of three dimensional (3D) cell migration. 
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7 APPENDIX 
7.1 Abbreviations 
2D Two dimensional 
3D Three dimensional 
AFM Atomic force microscope 
ANOVA Analysis of variance between groups 
ATM Ataxia-telangiectasia mutated 
ATP/ADP Adenosine triphosphate/diphosphate 
ATR ATM- and RAD3-related 
BSA Bovine serum albumin 
cDNA Complementary DNA 
ChB Chondramide B 
DDR DNA damage response 
DDS DNA double strand 
DMEM Dulbecco‘s Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNA Desoxyribunucleic acid 
DNA-PK DNA-dependent protein kinase 
Doxo Doxorubicin 
DSB DNA double strand breaks 
e. g. For example 
ECGM endothelial cell growth medium 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescence-activated cell sorting 
F-actin Filamentous actin 
FCS  Fetal calf serum 
FDR False discovery rate 
G-actin Globular actin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GM130 Golgi matrix protein 130 kDa 
GOLPH3 Golgi phosphoprotein 3 
HFS Hypotonic fluorochrome solution 
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HRP Horseradish peroxidase 
HUVEC Human umbilical vein endothelial cell 
IgG Immunoglobulin G 
mRNA Messenger ribonucleic acid 
MRTF-A Myocardin-related transcription factor-A 
Myo18A Myosin 18A 
NADH Nicotinamide adenine dinucleotide H 
NFAT Nuclear factor of activated T-cells 
no. Number 
o/n Overnight 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PI Propidium iodide 
PI4P Phosphatidylinositol-4-phosphate 
PKCε Protein kinase C ε 
PMSF Phenylmethanesulfonylfluoride 
PVDF Polyvinylidene difluoride 
ROS Reactive oxygen species  
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
Src Sarcoma 
SRF Serum response factor 
T/E Trypsin/EDTA 
TBS-T Tris-buffered saline and Tween 20 
Thr Threonine 
YP Yo-Pro-1 
γH2A.x Phospho-histone 2A.x 
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7.2 Units 
°C Celsius degree 
A Ampere 
Da Dalton 
g Gram 
H Hour 
Hz Hertz 
l Liter 
m Meter 
M Molar (mol/l) 
min Minute 
N Newton 
Pa Pascal 
V Volt 
W Watt 
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Liebe Karin, lieber Fabi, vielen Dank für die tolle Atmosphäre in unserem Labor. Fabi, dir 
möchte ich für die ruhigen Stunden am Morgen und die vertrauten Gespräche am Abend 
danken. Karin, vielen Dank für den Austausch unterhaltsamer Laborgeschehnisse und 
deine direkte und ehrliche Art.  
Auch dir Meli möchte ich herzlichst Danke sagen. Du warst während den drei 
gemeinsamen Jahren meine persönliche Stütze im Labor, hast mich immer auch ohne 
viele Worte verstanden und hattest bei größeren und kleineren Problemen immer einen 
ehrlichen Rat für mich, auch außerhalb vom Labor. 
Liebe/r Fabi, Karin, Katja und Meli, vielen Dank für die zahlreichen gemeinsamen Stunden 
im PB III Praktikum und die angenehme Atmosphäre während der Betreuung. 
Vielen Dank auch an alle, mit denen ich Konferenzen besuchen durfte und darüber hinaus 
viel Spaß hatte. Außerdem danke ich dem gesamten AK Vollmar für die herzliche Art, 
sowie Gemeinschaftlichkeit und dafür, dass ich wegen Euch jeden Tag gerne ins Labor 
gekommen bin und mich immer an diese Zeit erinnern werde. 
Mein herzlichster Dank, gilt auch meiner Familie und Freunden für die große 
Unterstützung und das immerwährende Vertrauen in mich. 
„MAN MUSS DAS UNMÖGLICHE VERSUCHEN, UM DAS MÖGLICHE ZU ERREICHEN.“ 
Hermann Hesse, (Deutscher Schriftsteller & Nobelpreisträger) 
Lieber Christian, zu guter Letzt möchte ich dir von ganzem Herzen Danke sagen. Danke 
dafür, dass ich mit deiner Hilfe das Unmögliche möglich machen konnte und dafür, dass 
du immer für mich da bist. 
